

US010596386B2

# (12) United States Patent

# Schwarz et al.

# (54) AESTHETIC METHOD OF BIOLOGICAL STRUCTURE TREATMENT BY MAGNETIC FIELD

- (71) Applicant: BTL Medical Technologies S.R.O., Prague (CZ)
- (72) Inventors: Tomás Schwarz, Prague (CZ); Ondra Prouza, Ricany u Prahy (CZ)
- (73) Assignee: **BTL Medical Technologies S.R.O.**, Prague (CZ)
- (\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.
- (21) Appl. No.: 15/601,719
- (22) Filed: May 22, 2017

### (65) **Prior Publication Data**

US 2018/0001106 A1 Jan. 4, 2018

### **Related U.S. Application Data**

- (60) Provisional application No. 62/357,679, filed on Jul.
   1, 2016, provisional application No. 62/440,905, filed (Continued)
- (51) Int. Cl. *A61N 2/00* (2006.01) *A61N 2/02* (2006.01)

(	Continued)

(Continued)

# (10) Patent No.: US 10,596,386 B2

# (45) **Date of Patent:** Mar. 24, 2020

(58) Field of Classification Search CPC ........... A61N 2/00; A61N 2/002; A61N 2/004; A61N 2/02; A61N 1/40; A61N 1/403; (Continued)

# (56) **References Cited**

#### U.S. PATENT DOCUMENTS

3,658,051 A	4/1972	MacLean et al.
3,915,151 A	10/1975	Kraus
	(Con	tinued)

#### FOREIGN PATENT DOCUMENTS

AU	2011265424 B2	7/2014
AU	2012244313 B2	11/2014
	(Cont	inued)

### OTHER PUBLICATIONS

Lin, et al., "Functional Magnetic Stimulation: A New Modality for Enhancing Systemic Fibrinolysis," Arch Phys Med Rehabil vol. 80, May 1999, pp. 545-550.


(Continued)

Primary Examiner — Carrie R Dorna (74) Attorney, Agent, or Firm — Sterne, Kessler, Goldstein & Fox P.L.L.C.

# (57) **ABSTRACT**

In methods for treating a patient, a time varying magnetic field is applied to a patient's body and causes a muscle contraction. The time-varying magnetic field may be monophasic, biphasic, polyphasic and/or static. The method may reduce adipose tissue, improve metabolism, blood and/or lymph circulation. The method may use combinations of treatments to enhance the visual appearance of the patient.

# 21 Claims, 4 Drawing Sheets



# **Related U.S. Application Data**

on Dec. 30, 2016, provisional application No. 62/440, 922, filed on Dec. 30, 2016.

(51) Int. Cl.

A61F 7/02	(2006.01)
A61F 7/00	(2006.01)

# (58) Field of Classification Search

See application file for complete search history.

# (56) **References Cited**

# U.S. PATENT DOCUMENTS

4,237,898	Α	12/1980	Whalley
4,315,503	Α	2/1982	Rayby et al.
4,454,883	Α	6/1984	Fellus
4,456,001	Α	6/1984	Pescatore
4,665,898	Α	5/1987	Costa
4,674,505	Α	6/1987	Pauli et al.
4,850,959	A	7/1989	Findl
4,993,413	Ā	2/1991	McLeod
5,067,940	Ā	11/1991	Liboff et al.
5,085,626	Â	2/1992	Frey
5,334,181	A	8/1994	Rubinsky et al.
5,401,233	A	3/1995	Erickson et al.
5,674,218	Â	10/1997	Rubinsky et al.
5,718,662	Ā	2/1998	Jalinous
5,766,124	A	6/1998	Polson
5,700,124	A	7/1998	Russell
5,782,743			
5,807,232	A	9/1998	Espinoza et al.
5,908,444	A	6/1999	Azure
5,984,854	A	11/1999	Ishikawa et al.
6,017,337	A	1/2000	Pira
6,032,675	A	3/2000	Rubinsky
6,063,108	Α	5/2000	Salansky et al.
6,086,525	А	7/2000	Davey et al.
6,099,459	А	8/2000	Jacobson
6,117,066	Α	9/2000	Abrams
6,141,985	Α	11/2000	Cluzeau et al.
6,179,769	B1	1/2001	Ishikawa et al.
6,179,770	B1	1/2001	Mould
6,213,933	B1	4/2001	Lin
6,223,750	B1	5/2001	Ishikawa et al.
6,350,276	B1	2/2002	Knowlton
6,402,678	B1	6/2002	Fischell et al.
6,418,345	B1	7/2002	Tepper et al.
6,527,694	B1	3/2003	Ishikawa et al.
6,569,078	B2	5/2003	Ishikawa et al.
6,605,080	BI	8/2003	Altshuler et al.
6,635,053	BI	10/2003	Lalonde et al.
6,749,624	B2	6/2004	Knowlton
6,889,090	B2	5/2005	Kreindel
6,939,287	BI	9/2005	Ardizzone et al.
6,960,202	B2	11/2005	Cluzeau et al.
7,030,764	B2 B2	4/2006	Smith et al.
	B2 B2	5/2006	Kreindel
7,041,100	B2 B2		
7,217,265		5/2007	Hennings et al.
7,276,058	B2	10/2007	Altshuler et al.
7,318,821	B2	1/2008	Lalonde et al.
7,351,252	B2	4/2008	Altshuler et al.
7,367,341	B2	5/2008	Anderson et al.
7,520,849	B1	4/2009	Simon
7,601,115	B2	10/2009	Riehl
7,608,035	B2	10/2009	Farone
7,740,574	B2	6/2010	Pilla et al.

7.744.600 DO	C (2010	F ( '
7,744,523 B2	6/2010	Epstein
7,785,358 B2	8/2010	Lach
7,854,754 B2	12/2010	Ting et al.
7,946,973 B2	5/2011	Peterchev
7,998,053 B2	8/2011	Aho
RE43,007 E	12/2011	Lalonde et al.
8,088,058 B2	1/2012	Juliana et al.
8,192,474 B2	6/2012	Levinson
	9/2012	Allison
8,285,390 B2	10/2012	Levinson et al.
8,337,539 B2	12/2012	Ting et al.
8,366,756 B2	2/2013	
		Tucek et al.
8,523,927 B2	9/2013	Levinson et al.
8,603,073 B2	12/2013	Allison
8,676,338 B2	3/2014	Levinson
8,702,774 B2	4/2014	Baker et al.
8,771,326 B2	7/2014	Myeong et al.
8,834,547 B2	9/2014	Anderson et al.
8,840,608 B2	9/2014	Anderson et al.
8,915,948 B2	12/2014	Altshuler et al.
8,932,338 B2	1/2015	Lim et al.
8,979,727 B2	3/2015	Ron et al.
8,998,791 B2	4/2015	Ron et al.
· · ·		
9,002,477 B2	4/2015	Burnett
9,028,469 B2	5/2015	Jones et al.
, ,	6/2015	Araya et al.
· · ·		
9,078,634 B2	7/2015	Gonzales et al.
9,132,031 B2	9/2015	Levinson et al.
· · ·		
- , ,	10/2015	Shanks et al.
9,308,120 B2	4/2016	Anderson et al.
9,314,368 B2	4/2016	Allison et al.
· · ·		
9,358,068 B2	6/2016	Schomacker et al.
9,358,149 B2	6/2016	Anderson et al.
9,375,345 B2	6/2016	Levinson et al.
9,398,975 B2	7/2016	Müller et al.
9,408,745 B2	8/2016	Levinson et al.
9,439,805 B2	9/2016	Gonzales et al.
, ,		
9,545,523 B2	1/2017	Nanda
9,586,057 B2	3/2017	Ladman et al.
9,610,429 B2	4/2017	Harris et al.
	5/2017	
9,636,519 B2		Ladman et al.
9,649,220 B2	5/2017	Anderson et al.
9,655,770 B2	5/2017	Levinson et al.
· · ·		
9,737,434 B2	8/2017	Allison
9,844,460 B2	12/2017	Weber et al.
9,844,461 B2	12/2017	Levinson et al.
	1/2018	
9,855,166 B2		Anderson et al.
9,861,421 B2	1/2018	O'Neil et al.
9,861,520 B2	1/2018	Baker et al.
	3/2018	
9,919,161 B2		Schwarz et al.
9,937,358 B2	4/2018	Schwarz et al.
9,974,519 B1	5/2018	Schwarz et al.
9,974,684 B2	5/2018	Anderson et al.
9,980,765 B2	5/2018	Avram et al.
10,092,346 B2	10/2018	Levinson
10,111,770 B2	10/2018	Harris et al.
10,111,774 B2	10/2018	Gonzales et al.
10,124,187 B2	11/2018	Schwarz et al.
10,201,380 B2	2/2019	Debenedictis et al.
10,245,439 B1	4/2019	
		Schwarz et al.
2001/0031906 A1	10/2001	Ishikawa et al.
2002/0049483 A1	4/2002	Knowlton
2003/0158585 A1	8/2003	Burnett
2003/0220674 A1	11/2003	Anderson et al.
2004/0073079 A1	4/2004	Altshuler et al.
2004/0102768 A1	5/2004	Cluzeau et al.
2004/0210287 A1	10/2004	Greene
2005/0090814 A1	4/2005	LaLonde et al.
2005/0251120 A1	11/2005	Anderson et al.
2006/0152301 A1	7/2006	Rohwedder
2006/0187607 A1	8/2006	Mo
2006/0287566 A1	12/2006	Zangen et al.
2007/0010861 A1	1/2007	Anderson et al.
2007/0083237 A1	4/2007	Teruel
2007/0088413 A1	4/2007	Weber et al.
2007/0198071 A1	8/2007	Ting et al.
2007/0255362 A1		
	11/2007	
	11/2007	Levinson et al.
2007/0250502 A1	11/2007 11/2007	Levinson et al. Levinson
2007/0270925 A1	11/2007	Levinson

#### (56) **References** Cited

# U.S. PATENT DOCUMENTS

2008/0077202 A1	3/2008	Levinson
2008/0077211 A1	3/2008	Levinson et al.
2008/0103565 A1	5/2008	Altshuler et al.
2008/0188915 A1	8/2008	Mills et al.
2008/0249350 A1	10/2008	Marchitto et al.
2008/0262287 A1	10/2008	Dussau
2008/0287839 A1	11/2008	Rosen et al.
2008/0306325 A1*	* 12/2008	Burnett A61N 2/02
		600/13
2008/0306326 A1	12/2008	Epstein
2009/0005631 A1	1/2009	Simenhaus et al.
2009/0018384 A1	1/2009	Boyden et al.
2009/0018623 A1	1/2009	Levinson et al.
2009/0018624 A1	1/2009	Levinson et al.
2009/0018625 A1	1/2009	Levinson et al.
2009/0018626 A1	1/2009	Levinson et al.
2009/0018627 A1	1/2009	Levinson et al.
2009/0024193 A1	1/2009	Altshuler et al.
2009/0108969 A1	4/2009	Sims et al.
2009/0118722 A1	5/2009	Ebbers et al.
2009/0149929 A1	6/2009	Levinson et al.
2010/0036368 A1*	2/2010	England A61B 18/14
		606/33
2010/0081971 A13	<sup>k</sup> 4/2010	Allison A61B 34/10
		601/2
2010/0087699 A1	4/2010	Peterchev
2010/0121131 A1	5/2010	Mathes
2010/0152522 A1	6/2010	Roth et al.
2010/0152824 A1	6/2010	Allison
2010/0160712 A1	6/2010	Burnett et al.
2010/0179372 A1	7/2010	Glassman
2010/0222629 A1	9/2010	Burnett et al.
2010/0280582 A1	11/2010	Baker et al.
2010/0309689 A1	12/2010	Coulson
2010/0331603 A1	12/2010	Szecsi
2011/0021863 A1	1/2011	Burnett
2011/0066216 A1	3/2011	Ting et al.
LOID COOLIC III		
2011/0077451 41	2/2011	
2011/0077451 A1	3/2011	Marchitto et al.
2011/0087312 A1	4/2011	Marchitto et al. Shanks et al.
	4/2011	Marchitto et al.
2011/0087312 A1	4/2011	Marchitto et al. Shanks et al.
2011/0087312 A1 2011/0130618 A1	4/2011	Marchitto et al. Shanks et al. Ron Edoute A61N 1/328
2011/0087312 A1 2011/0130618 A1 2011/0224761 A1	4/2011 6/2011 9/2011	Marchitto et al. Shanks et al. Ron Edoute A61N 1/328 600/14 Manstein
2011/0087312 A1 2011/0130618 A1 2011/0224761 A1 2011/0238050 A1	<ul> <li>4/2011</li> <li>6/2011</li> <li>9/2011</li> <li>9/2011</li> </ul>	Marchitto et al. Shanks et al. Ron Edoute A61N 1/328 600/14 Manstein Allison et al.
2011/0087312 A1 2011/0130618 A1 2011/0224761 A1 2011/0238050 A1 2011/0238051 A1	4/2011 6/2011 9/2011 9/2011 9/2011	Marchitto et al. Shanks et al. Ron Edoute A61N 1/328 600/14 Manstein Allison et al. Levinson et al.
2011/0087312 A1 2011/0130618 A1 2011/0224761 A1 2011/0238050 A1 2011/0238051 A1 2011/0263925 A1	4/2011 9/2011 9/2011 9/2011 9/2011 10/2011	Marchitto et al. Shanks et al. Ron Edoute A61N 1/328 600/14 Manstein Allison et al. Levinson et al. Bratton
2011/0087312 A1 2011/0130618 A1 2011/0224761 A1 2011/0238050 A1 2011/0238051 A1	4/2011 6/2011 9/2011 9/2011 9/2011	Marchitto et al. Shanks et al. Ron Edoute A61N 1/328 600/14 Manstein Allison et al. Levinson et al.
2011/0087312 A1 2011/0130618 A1 2011/0224761 A1 2011/0238050 A1 2011/0238051 A1 2011/0263925 A1	4/2011 9/2011 9/2011 9/2011 9/2011 10/2011	Marchitto et al. Shanks et al. Ron Edoute A61N 1/328 600/14 Manstein Allison et al. Levinson et al. Bratton
2011/0087312 A1 2011/0130618 A1 2011/0224761 A1 2011/0238050 A1 2011/0238051 A1 2011/0263925 A1 2011/0300079 A1 2012/0022518 A1	4/2011 9/2011 9/2011 9/2011 9/2011 10/2011 12/2011 1/2012	Marchitto et al. Shanks et al. Ron Edoute A61N 1/328 600/14 Manstein Allison et al. Levinson et al. Bratton Martens et al. Levinson
2011/0087312 A1 2011/0130618 A1 2011/0224761 A1 2011/0238050 A1 2011/0238051 A1 2011/0263925 A1 2011/0300079 A1 2012/0022518 A1 2012/0053449 A1	<pre>4/2011 6/2011 9/2011 9/2011 9/2011 10/2011 12/2011 1/2012 3/2012</pre>	Marchitto et al. Shanks et al. Ron Edoute A61N 1/328 600/14 Manstein Allison et al. Levinson et al. Bratton Martens et al. Levinson Moses
2011/0087312 A1 2011/0130618 A1 2011/0224761 A1 2011/0238050 A1 2011/0238051 A1 2011/0263925 A1 2012/0022518 A1 2012/0053449 A1 2012/0197361 A1	4/2011 6/2011 9/2011 9/2011 10/2011 12/2011 1/2012 3/2012 8/2012	Marchitto et al. Shanks et al. Ron Edoute A61N 1/328 600/14 Manstein Allison et al. Levinson et al. Bratton Martens et al. Levinson Moses Gonzales et al.
2011/0087312 A1 2011/0130618 A1 2011/0238050 A1 2011/0238050 A1 2011/0263925 A1 2011/0263925 A1 2012/0022518 A1 2012/0053449 A1 2012/0197361 A1 2012/0215210 A1	<pre>4/2011 6/2011 9/2011 9/2011 9/2011 10/2011 1/2011 1/2012 3/2012 8/2012 8/2012</pre>	Marchitto et al. Shanks et al. Ron Edoute A61N 1/328 600/14 Manstein Allison et al. Levinson et al. Bratton Martens et al. Levinson Moses Gonzales et al. Brown et al.
2011/0087312 A1 2011/0130618 A1 2011/0224761 A1 2011/0238050 A1 2011/0238051 A1 2011/0263925 A1 2011/0300079 A1 2012/0022518 A1 2012/0053449 A1 2012/0197361 A1 2012/0215210 A1 2012/0239123 A1	<pre>4/2011 6/2011 9/2011 9/2011 9/2011 10/2011 1/2012 3/2012 8/2012 8/2012 9/2012</pre>	Marchitto et al. Shanks et al. Ron Edoute
2011/0087312 A1 2011/0130618 A1 2011/0238050 A1 2011/0238051 A1 2011/0238051 A1 2011/0263925 A1 2012/0022518 A1 2012/0022518 A1 2012/0053449 A1 2012/017361 A1 2012/0215210 A1 2012/0239123 A1 2012/0302821 A1	4/2011 6/2011 9/2011 9/2011 10/2011 10/2011 1/2012 3/2012 8/2012 8/2012 8/2012 11/2012	Marchitto et al. Shanks et al. Ron Edoute A61N 1/328 600/14 Manstein Allison et al. Levinson et al. Bratton Martens et al. Levinson Moses Gonzales et al. Brown et al.
2011/0087312 A1 2011/0130618 A1 2011/0224761 A1 2011/0238050 A1 2011/0238051 A1 2011/0263925 A1 2011/0300079 A1 2012/0022518 A1 2012/0053449 A1 2012/0197361 A1 2012/0215210 A1 2012/0239123 A1	4/2011 6/2011 9/2011 9/2011 10/2011 12/2011 1/2012 3/2012 8/2012 8/2012 9/2012 11/2012	Marchitto et al. Shanks et al. Ron Edoute
2011/0087312 A1 2011/0130618 A1 2011/0234761 A1 2011/0238050 A1 2011/0238051 A1 2011/0263925 A1 2012/0022518 A1 2012/0022518 A1 2012/0053449 A1 2012/017361 A1 2012/0215210 A1 2012/0239123 A1 2012/0302821 A1	4/2011 6/2011 9/2011 9/2011 10/2011 12/2011 1/2012 3/2012 8/2012 8/2012 9/2012 11/2012	Marchitto et al. Shanks et al. Ron Edoute
2011/0087312 A1 2011/0130618 A1 2011/0224761 A1 2011/0238050 A1 2011/0238051 A1 2011/0263925 A1 2011/0300079 A1 2012/0022518 A1 2012/0053449 A1 2012/0197361 A1 2012/0215210 A1 2012/0239123 A1 2012/0310033 A1	4/2011 6/2011 9/2011 9/2011 10/2011 1/2012 3/2012 8/2012 8/2012 8/2012 9/2012 11/2012 12/2012	Marchitto et al. Shanks et al. Ron Edoute
2011/0087312 A1 2011/0130618 A1 2011/0224761 A1 2011/0238050 A1 2011/0238050 A1 2011/0263925 A1 2011/0300079 A1 2012/0022518 A1 2012/0053449 A1 2012/0197361 A1 2012/0215210 A1 2012/0239123 A1 2012/0302821 A1 2012/0310033 A1	<pre>4/2011 6/2011 9/2011 9/2011 10/2011 12/2011 1/2012 8/2012 8/2012 8/2012 8/2012 11/2012 * 12/2012</pre>	Marchitto et al. Shanks et al. Ron Edoute A61N 1/328 600/14 Manstein Allison et al. Levinson et al. Bratton Martens et al. Levinson Moses Gonzales et al. Brown et al. Brown et al. Burnett Muntermann A61N 2/004 600/9 Weyh et al.
2011/0087312 A1 2011/0130618 A1 2011/0224761 A1 2011/0238050 A1 2011/0238051 A1 2011/0263925 A1 2011/0300079 A1 2012/0022518 A1 2012/0053449 A1 2012/0197361 A1 2012/0215210 A1 2012/0239123 A1 2012/0310033 A1	<pre>4/2011 6/2011 9/2011 9/2011 10/2011 12/2011 1/2012 8/2012 8/2012 8/2012 8/2012 11/2012 * 12/2012</pre>	Marchitto et al. Shanks et al. Ron Edoute A61N 1/328 600/14 Manstein Allison et al. Levinson et al. Bratton Martens et al. Levinson Moses Gonzales et al. Brown et al. Brown et al. Burnett Muntermann A61N 2/004 600/9 Weyh et al. Susedik
2011/0087312 A1 2011/0130618 A1 2011/0224761 A1 2011/0238050 A1 2011/0238051 A1 2011/0263925 A1 2012/0022518 A1 2012/002518 A1 2012/0197361 A1 2012/0215210 A1 2012/0239123 A1 2012/0302821 A1 2012/0310033 A1 2013/0030239 A1 2013/0053620 A1	<ul> <li>4/2011</li> <li>6/2011</li> <li>9/2011</li> <li>9/2011</li> <li>9/2011</li> <li>10/2011</li> <li>12/2011</li> <li>1/2012</li> <li>3/2012</li> <li>8/2012</li> <li>8/2012</li> <li>9/2012</li> <li>11/2012</li> <li>12/2012</li> <li>12/2013</li> <li>2/2013</li> </ul>	Marchitto et al. Shanks et al. Ron Edoute
2011/0087312 A1 2011/0130618 A1 2011/0224761 A1 2011/0238050 A1 2011/0238050 A1 2011/0263925 A1 2011/0300079 A1 2012/0022518 A1 2012/0053449 A1 2012/0197361 A1 2012/0215210 A1 2012/0239123 A1 2012/0302821 A1 2012/0310033 A1	<ul> <li>4/2011</li> <li>6/2011</li> <li>9/2011</li> <li>9/2011</li> <li>9/2011</li> <li>10/2011</li> <li>10/2011</li> <li>12/2011</li> <li>1/2012</li> <li>3/2012</li> <li>8/2012</li> <li>8/2012</li> <li>9/2012</li> <li>11/2012</li> <li>*</li> <li>1/2013</li> <li>2/2013</li> <li>3/2013</li> </ul>	Marchitto et al. Shanks et al. Ron Edoute A61N 1/328 600/14 Manstein Allison et al. Levinson et al. Bratton Martens et al. Levinson Moses Gonzales et al. Brown et al. Brown et al. Burnett Muntermann A61N 2/004 600/9 Weyh et al. Susedik
2011/0087312 A1 2011/0130618 A1 2011/0224761 A1 2011/0238050 A1 2011/0238051 A1 2011/0263925 A1 2012/0022518 A1 2012/002518 A1 2012/0197361 A1 2012/0215210 A1 2012/0239123 A1 2012/0302821 A1 2012/0310033 A1 2013/0030239 A1 2013/0053620 A1	<ul> <li>4/2011</li> <li>6/2011</li> <li>9/2011</li> <li>9/2011</li> <li>9/2011</li> <li>10/2011</li> <li>12/2011</li> <li>1/2012</li> <li>3/2012</li> <li>8/2012</li> <li>8/2012</li> <li>9/2012</li> <li>11/2012</li> <li>12/2012</li> <li>12/2013</li> <li>2/2013</li> </ul>	Marchitto et al. Shanks et al. Ron Edoute
2011/0087312 A1 2011/0130618 A1 2011/0224761 A1 2011/0238050 A1 2011/0238051 A1 2011/0263925 A1 2012/0022518 A1 2012/0023912 A1 2012/0053449 A1 2012/0197361 A1 2012/0239123 A1 2012/0310033 A1 2013/0030239 A1 2013/0053620 A1 2013/0066309 A1 2013/0079684 A1	<ul> <li>4/2011</li> <li>6/2011</li> <li>9/2011</li> <li>9/2011</li> <li>9/2011</li> <li>10/2011</li> <li>10/2011</li> <li>12/2012</li> <li>3/2012</li> <li>8/2012</li> <li>8/2012</li> <li>8/2012</li> <li>9/2012</li> <li>11/2012</li> <li>12/2013</li> <li>2/2013</li> <li>3/2013</li> <li>3/2013</li> <li>3/2013</li> </ul>	Marchitto et al. Shanks et al. Ron Edoute A61N 1/328 600/14 Manstein Allison et al. Levinson et al. Bratton Martens et al. Levinson Moses Gonzales et al. Brown et al. Burnett Muntermann A61N 2/004 600/9 Weyh et al. Susedik
2011/0087312 A1 2011/0130618 A1 2011/0224761 A1 2011/0238050 A1 2011/0238050 A1 2011/0263925 A1 2012/0022518 A1 2012/0053449 A1 2012/0197361 A1 2012/0239123 A1 2012/0302821 A1 2012/0310033 A1 2013/0030239 A1 2013/0053620 A1 2013/0066309 A1 2013/0079684 A1 2013/0103127 A1	<ul> <li>4/2011</li> <li>6/2011</li> <li>9/2011</li> <li>9/2011</li> <li>9/2011</li> <li>10/2011</li> <li>12/2011</li> <li>12/2012</li> <li>3/2012</li> <li>8/2012</li> <li>8/2012</li> <li>9/2012</li> <li>11/2012</li> <li>12/2012</li> <li>12/2013</li> <li>2/2013</li> <li>3/2013</li> <li>3/2013</li> <li>4/2013</li> </ul>	Marchitto et al. Shanks et al. Ron Edoute
2011/0087312 A1 2011/0130618 A1 2011/0238050 A1 2011/0238050 A1 2011/0238051 A1 2011/0263925 A1 2012/0022518 A1 2012/002518 A1 2012/0053449 A1 2012/0197361 A1 2012/0215210 A1 2012/0302821 A1 2012/0310033 A1 2013/0030239 A1 2013/0066309 A1 2013/0066309 A1 2013/0079684 A1 2013/0103127 A1 2013/0116758 A1	<ul> <li>4/2011</li> <li>6/2011</li> <li>9/2011</li> <li>9/2011</li> <li>9/2011</li> <li>10/2011</li> <li>12/2011</li> <li>1/2012</li> <li>8/2012</li> <li>8/2012</li> <li>8/2012</li> <li>11/2012</li> <li>12/2013</li> <li>2/2013</li> <li>3/2013</li> <li>3/2013</li> <li>4/2013</li> <li>5/2013</li> </ul>	Marchitto et al. Shanks et al. Ron Edoute A61N 1/328 600/14 Manstein Allison et al. Levinson et al. Bratton Martens et al. Levinson Moses Gonzales et al. Brown et al. Burnett Muntermann A61N 2/004 600/9 Weyh et al. Susedik A61N 1/406 600/10 Levinson Rosen et al. Mueller et al. Levinson et al.
2011/0087312 A1 2011/0130618 A1 2011/0224761 A1 2011/0238050 A1 2011/0238050 A1 2011/0263925 A1 2012/0022518 A1 2012/0053449 A1 2012/0197361 A1 2012/0197361 A1 2012/0239123 A1 2012/0302821 A1 2012/0310033 A1 2013/0030239 A1 2013/0066309 A1 2013/0066309 A1 2013/0079684 A1 2013/016758 A1 2013/0116758 A1	<ul> <li>4/2011</li> <li>6/2011</li> <li>9/2011</li> <li>9/2011</li> <li>9/2011</li> <li>10/2011</li> <li>12/2011</li> <li>1/2012</li> <li>3/2012</li> <li>8/2012</li> <li>8/2012</li> <li>9/2012</li> <li>11/2012</li> <li>* 2/2013</li> <li>3/2013</li> <li>3/2013</li> <li>3/2013</li> <li>5/2013</li> <li>5/2013</li> </ul>	Marchitto et al. Shanks et al. Ron Edoute
2011/0087312 A1 2011/0130618 A1 2011/0238050 A1 2011/0238050 A1 2011/0238051 A1 2011/0263925 A1 2012/0022518 A1 2012/002518 A1 2012/0053449 A1 2012/0197361 A1 2012/0215210 A1 2012/0302821 A1 2012/0310033 A1 2013/0030239 A1 2013/0066309 A1 2013/0066309 A1 2013/0079684 A1 2013/0103127 A1 2013/0116758 A1	<ul> <li>4/2011</li> <li>6/2011</li> <li>9/2011</li> <li>9/2011</li> <li>9/2011</li> <li>10/2011</li> <li>12/2011</li> <li>1/2012</li> <li>8/2012</li> <li>8/2012</li> <li>8/2012</li> <li>11/2012</li> <li>12/2013</li> <li>2/2013</li> <li>3/2013</li> <li>3/2013</li> <li>4/2013</li> <li>5/2013</li> </ul>	Marchitto et al. Shanks et al. Ron Edoute A61N 1/328 600/14 Manstein Allison et al. Levinson et al. Bratton Martens et al. Levinson Moses Gonzales et al. Brown et al. Burnett Muntermann A61N 2/004 600/9 Weyh et al. Susedik A61N 1/406 600/10 Levinson Rosen et al. Mueller et al. Levinson et al.
2011/0087312 A1 2011/0130618 A1 2011/0224761 A1 2011/0238050 A1 2011/0238050 A1 2011/0263925 A1 2012/0022518 A1 2012/0053449 A1 2012/0197361 A1 2012/0197361 A1 2012/0239123 A1 2012/0302821 A1 2012/0310033 A1 2013/0030239 A1 2013/0066309 A1 2013/0066309 A1 2013/0079684 A1 2013/016758 A1 2013/0116758 A1	<ul> <li>4/2011</li> <li>6/2011</li> <li>9/2011</li> <li>9/2011</li> <li>9/2011</li> <li>10/2011</li> <li>12/2011</li> <li>1/2012</li> <li>3/2012</li> <li>8/2012</li> <li>8/2012</li> <li>9/2012</li> <li>11/2012</li> <li>* 2/2013</li> <li>3/2013</li> <li>3/2013</li> <li>3/2013</li> <li>5/2013</li> <li>5/2013</li> </ul>	Marchitto et al. Shanks et al. Ron Edoute
2011/0087312 A1 2011/0130618 A1 2011/0224761 A1 2011/0238050 A1 2011/0238051 A1 2011/0263925 A1 2012/0022518 A1 2012/0053449 A1 2012/0197361 A1 2012/0239123 A1 2012/0310033 A1 2013/0030239 A1 2013/0053620 A1 2013/006309 A1 2013/0079684 A1 2013/0103127 A1 2013/0116758 A1 2013/0123568 A1 2013/0123764 A1	<ul> <li>4/2011</li> <li>6/2011</li> <li>9/2011</li> <li>9/2011</li> <li>9/2011</li> <li>10/2011</li> <li>10/2011</li> <li>12/2012</li> <li>8/2012</li> <li>8/2012</li> <li>8/2012</li> <li>8/2012</li> <li>8/2012</li> <li>12/2012</li> <li>1/2013</li> <li>2/2013</li> <li>3/2013</li> <li>3/2013</li> <li>3/2013</li> <li>5/2013</li> <li>5/2013</li> <li>5/2013</li> </ul>	Marchitto et al. Shanks et al. Ron Edoute
2011/0087312 A1 2011/0130618 A1 2011/0238050 A1 2011/0238050 A1 2011/0238051 A1 2011/0263925 A1 2012/002518 A1 2012/0053449 A1 2012/0197361 A1 2012/0215210 A1 2012/0302821 A1 2012/0302821 A1 2012/0310033 A1 2013/0053620 A1 2013/0066309 A1 2013/0079684 A1 2013/0016758 A1 2013/0116759 A1 2013/0116759 A1 2013/0123568 A1	<ul> <li>4/2011</li> <li>6/2011</li> <li>9/2011</li> <li>9/2011</li> <li>9/2011</li> <li>10/2011</li> <li>10/2011</li> <li>12/2012</li> <li>8/2012</li> <li>8/2012</li> <li>8/2012</li> <li>8/2012</li> <li>8/2012</li> <li>12/2012</li> <li>1/2013</li> <li>2/2013</li> <li>3/2013</li> <li>3/2013</li> <li>3/2013</li> <li>5/2013</li> <li>5/2013</li> <li>5/2013</li> </ul>	Marchitto et al. Shanks et al. Ron Edoute
2011/0087312 A1 2011/0130618 A1 2011/0224761 A1 2011/0238050 A1 2011/0238050 A1 2011/0263925 A1 2012/0053449 A1 2012/0053449 A1 2012/0197361 A1 2012/0239123 A1 2012/0302821 A1 2012/0310033 A1 2013/0030239 A1 2013/006309 A1 2013/006309 A1 2013/0079684 A1 2013/0103127 A1 2013/016758 A1 2013/0123764 A1 2013/0123764 A1 2013/0123764 A1	<ul> <li>4/2011</li> <li>6/2011</li> <li>9/2011</li> <li>9/2011</li> <li>9/2011</li> <li>10/2011</li> <li>12/2011</li> <li>12/2012</li> <li>8/2012</li> <li>8/2012</li> <li>8/2012</li> <li>12/2012</li> <li>11/2012</li> <li>12/2013</li> <li>2/2013</li> <li>3/2013</li> <li>3/2013</li> <li>3/2013</li> <li>5/2013</li> <li>5/2013</li> <li>5/2013</li> </ul>	Marchitto et al. Shanks et al. Ron Edoute A61N 1/328 600/14 Manstein Allison et al. Levinson et al. Bratton Martens et al. Levinson Moses Gonzales et al. Brown et al. Burnett Muntermann A61N 2/004 600/9 Weyh et al. Susedik A61N 1/406 600/10 Levinson Rosen et al. Mueller et al. Levinson et al. Levinson et al. Hamilton et al. Zarsky et al. Zarsky et al. Zarsky A61N 1/40
2011/0087312 A1 2011/0130618 A1 2011/0224761 A1 2011/0238050 A1 2011/0238050 A1 2011/0238051 A1 2011/0263925 A1 2012/002518 A1 2012/002518 A1 2012/0053449 A1 2012/0197361 A1 2012/0239123 A1 2012/0302821 A1 2012/0310033 A1 2013/0030239 A1 2013/0066309 A1 2013/0066309 A1 2013/0079684 A1 2013/0103127 A1 2013/0116758 A1 2013/0123765 A1 2013/0123765 A1 2013/0131764 A1	<ul> <li>4/2011</li> <li>6/2011</li> <li>9/2011</li> <li>9/2011</li> <li>9/2011</li> <li>10/2011</li> <li>12/2011</li> <li>1/2012</li> <li>8/2012</li> <li>8/2012</li> <li>9/2012</li> <li>11/2012</li> <li>2/2013</li> <li>3/2013</li> <li>3/2013</li> <li>3/2013</li> <li>5/2013</li> <li>5/2013</li> <li>5/2013</li> <li>5/2013</li> </ul>	Marchitto et al. Shanks et al. Ron Edoute A61N 1/328 600/14 Manstein Allison et al. Levinson et al. Bratton Martens et al. Levinson Moses Gonzales et al. Brown et al. Burnett Muntermann A61N 2/004 600/9 Weyh et al. Susedik A61N 1/406 600/10 Levinson Rosen et al. Mueller et al. Levinson et al. Garage et al. Mueller et al. Levinson et al. Carsky et al. Zarsky et al. Carsey et al.
2011/0087312 A1 2011/0130618 A1 2011/0224761 A1 2011/0238050 A1 2011/0238050 A1 2011/0263925 A1 2012/0053449 A1 2012/0053449 A1 2012/0197361 A1 2012/0239123 A1 2012/0302821 A1 2012/0310033 A1 2013/0030239 A1 2013/006309 A1 2013/006309 A1 2013/0079684 A1 2013/0103127 A1 2013/016758 A1 2013/0123764 A1 2013/0123764 A1 2013/0123764 A1	<ul> <li>4/2011</li> <li>6/2011</li> <li>9/2011</li> <li>9/2011</li> <li>9/2011</li> <li>10/2011</li> <li>12/2011</li> <li>1/2012</li> <li>8/2012</li> <li>8/2012</li> <li>9/2012</li> <li>11/2012</li> <li>2/2013</li> <li>3/2013</li> <li>3/2013</li> <li>3/2013</li> <li>5/2013</li> <li>5/2013</li> <li>5/2013</li> <li>5/2013</li> </ul>	Marchitto et al. Shanks et al. Ron Edoute A61N 1/328 600/14 Manstein Allison et al. Levinson et al. Bratton Martens et al. Levinson Moses Gonzales et al. Brown et al. Burnett Muntermann A61N 2/004 600/9 Weyh et al. Susedik A61N 1/406 600/10 Levinson Rosen et al. Mueller et al. Levinson et al. Garage et al. Mueller et al. Levinson et al. Carsky et al. Zarsky et al. Carsey et al.
2011/0087312 A1 2011/0130618 A1 2011/0224761 A1 2011/0238050 A1 2011/0238050 A1 2011/0238051 A1 2011/0263925 A1 2012/002518 A1 2012/002518 A1 2012/0053449 A1 2012/0197361 A1 2012/0239123 A1 2012/0302821 A1 2012/0310033 A1 2013/0030239 A1 2013/0066309 A1 2013/0066309 A1 2013/0079684 A1 2013/0103127 A1 2013/0116758 A1 2013/0123765 A1 2013/0123765 A1 2013/0131764 A1	<ul> <li>4/2011</li> <li>6/2011</li> <li>9/2011</li> <li>9/2011</li> <li>9/2011</li> <li>10/2011</li> <li>12/2011</li> <li>1/2012</li> <li>8/2012</li> <li>8/2012</li> <li>9/2012</li> <li>11/2012</li> <li>2/2013</li> <li>3/2013</li> <li>3/2013</li> <li>3/2013</li> <li>5/2013</li> <li>5/2013</li> <li>5/2013</li> <li>5/2013</li> </ul>	Marchitto et al. Shanks et al. Ron Edoute A61N 1/328 600/14 Manstein Allison et al. Levinson et al. Bratton Martens et al. Levinson Moses Gonzales et al. Brown et al. Weber et al. Burnett Muntermann A61N 2/004 600/9 Weyh et al. Susedik A61N 1/406 600/10 Levinson Rosen et al. Mueller et al. Levinson et al. Carsky et al. Zarsky et al. Corve Phillips
2011/0087312 A1 2011/0130618 A1 2011/0238050 A1 2011/0238050 A1 2011/0238051 A1 2011/0263925 A1 2012/002518 A1 2012/002518 A1 2012/0053449 A1 2012/0053449 A1 2012/0197361 A1 2012/0215210 A1 2012/0302821 A1 2012/0310033 A1 2013/0030239 A1 2013/0053620 A1 2013/0066309 A1 2013/0079684 A1 2013/0103127 A1 2013/016758 A1 2013/0123568 A1 2013/0123764 A1 2013/0123765 A1 2013/0131764 A1 2013/0137918 A1	<ul> <li>4/2011</li> <li>6/2011</li> <li>9/2011</li> <li>9/2011</li> <li>9/2011</li> <li>10/2011</li> <li>12/2011</li> <li>1/2012</li> <li>8/2012</li> <li>8/2012</li> <li>9/2012</li> <li>11/2012</li> <li>* 2/2013</li> <li>3/2013</li> <li>3/2013</li> <li>3/2013</li> <li>5/2013</li> <li>5/2013</li> <li>5/2013</li> <li>* 5/2013</li> <li>* 5/2013</li> </ul>	Marchitto et al. Shanks et al. Ron Edoute
2011/0087312         A1           2011/0130618         A1           2011/0224761         A1           2011/0238050         A1           2011/0238050         A1           2011/0238051         A1           2011/0238051         A1           2011/0263925         A1           2012/0022518         A1           2012/00239123         A1           2012/0239123         A1           2012/0300323         A1           2013/0030239         A1           2013/0030239         A1           2013/0066309         A1           2013/0103127         A1           2013/0103127         A1           2013/0116758         A1           2013/0123764         A1           2013/0123765         A1           2013/0123764         A1           2013/0137918         A1           2013/0137918         A1	<ul> <li>4/2011</li> <li>6/2011</li> <li>9/2011</li> <li>9/2011</li> <li>9/2011</li> <li>10/2011</li> <li>12/2011</li> <li>12/2012</li> <li>8/2012</li> <li>8/2012</li> <li>8/2012</li> <li>8/2012</li> <li>8/2012</li> <li>12/2012</li> <li>12/2013</li> <li>3/2013</li> <li>3/2013</li> <li>3/2013</li> <li>3/2013</li> <li>5/2013</li> <li>5/2013</li> <li>5/2013</li> <li>5/2013</li> <li>5/2013</li> <li>5/2013</li> <li>6/2013</li> </ul>	Marchitto et al. Shanks et al. Ron Edoute A61N 1/328 600/14 Manstein Allison et al. Levinson et al. Bratton Martens et al. Bratton Moses Gonzales et al. Brown et al. Brown et al. Burnett Muntermann A61N 2/004 600/9 Weyh et al. Susedik A61N 1/406 600/10 Levinson Rosen et al. Levinson et al. Levinson et al. Levinson et al. Levinson et al. Levinson et al. Levinson et al. Carsky et al. Zarsky et al. Zarsky et al. Zarsky et al. Cove Phillips
2011/0087312         A1           2011/0130618         A1           2011/0224761         A1           2011/0238050         A1           2011/0238050         A1           2011/0238051         A1           2011/0238051         A1           2011/0263925         A1           2012/0022518         A1           2012/0053449         A1           2012/0053449         A1           2012/0239123         A1           2012/0302821         A1           2012/0310033         A1           2013/0030239         A1           2013/00066309         A1           2013/0079684         A1           2013/0116758         A1           2013/0123764         A1           2013/0123765         A1           2013/0123764         A1           2013/0131764         A1           2013/0131764         A1           2013/0131764         A1           2013/0137918         A1           2013/0150653         A1           2013/0150653         A1           2013/0158440         A1	<ul> <li>4/2011</li> <li>6/2011</li> <li>9/2011</li> <li>9/2011</li> <li>9/2011</li> <li>10/2011</li> <li>12/2011</li> <li>12/2012</li> <li>8/2012</li> <li>8/2012</li> <li>8/2012</li> <li>9/2012</li> <li>12/2012</li> <li>12/2013</li> <li>2/2013</li> <li>3/2013</li> <li>3/2013</li> <li>3/2013</li> <li>5/2013</li> <li>5/2013</li> <li>5/2013</li> <li>5/2013</li> <li>5/2013</li> <li>5/2013</li> <li>6/2013</li> <li>6/2013</li> <li>6/2013</li> </ul>	Marchitto et al. Shanks et al. Ron Edoute A61N 1/328 600/14 Manstein Allison et al. Levinson et al. Bratton Martens et al. Levinson Moses Gonzales et al. Brown et al. Burnett Muntermann A61N 2/004 600/9 Weyh et al. Susedik A61N 1/406 600/10 Levinson Rosen et al. Mueller et al. Levinson et al. Levinson et al. Levinson et al. Levinson et al. Levinson et al. Carsky et al. Zarsky et al. Zarsky et al. Zarsky et al. Zarsky et al. Borsody Allison
2011/0087312         A1           2011/0130618         A1           2011/0224761         A1           2011/0238050         A1           2011/0238050         A1           2011/0238050         A1           2011/0238050         A1           2011/0238050         A1           2011/023925         A1           2012/0053449         A1           2012/0197361         A1           2012/0239123         A1           2012/0302821         A1           2012/0310033         A1           2013/0030239         A1           2013/0066309         A1           2013/0079684         A1           2013/013127         A1           2013/013127         A1           2013/0123764         A1           2013/0123764         A1           2013/0123764         A1           2013/0131764         A1           2013/0131764         A1           2013/0130150653         A1           2013/0150653         A1           2013/0158634         A1	<ul> <li>4/2011</li> <li>6/2011</li> <li>9/2011</li> <li>9/2011</li> <li>9/2011</li> <li>9/2011</li> <li>10/2011</li> <li>12/2011</li> <li>12/2012</li> <li>8/2012</li> <li>8/2012</li> <li>8/2012</li> <li>11/2012</li> <li>12/2012</li> <li>12/2013</li> <li>2/2013</li> <li>3/2013</li> <li>3/2013</li> <li>3/2013</li> <li>5/2013</li> <li>5/2013</li> <li>5/2013</li> <li>5/2013</li> <li>5/2013</li> <li>6/2013</li> <li>6/2013</li> <li>6/2013</li> <li>6/2013</li> </ul>	Marchitto et al. Shanks et al. Ron Edoute A61N 1/328 600/14 Manstein Allison et al. Levinson et al. Bratton Martens et al. Levinson Moses Gonzales et al. Brown et al. Burnett Muntermann A61N 2/004 600/9 Weyh et al. Susedik A61N 1/406 600/10 Levinson Rosen et al. Mueller et al. Levinson et al. Levinson et al. Levinson et al. Zarsky et al. Zarsky et al. Zarsky et al. Zarsky et al. Borsody Allison Edoute
2011/0087312         A1           2011/0130618         A1           2011/0224761         A1           2011/0238050         A1           2011/0238050         A1           2011/0238051         A1           2011/0238051         A1           2011/0263925         A1           2012/0022518         A1           2012/0053449         A1           2012/0053449         A1           2012/0239123         A1           2012/0302821         A1           2012/0310033         A1           2013/0030239         A1           2013/00066309         A1           2013/0079684         A1           2013/0116758         A1           2013/0123764         A1           2013/0123765         A1           2013/0123764         A1           2013/0131764         A1           2013/0131764         A1           2013/0131764         A1           2013/0137918         A1           2013/0150653         A1           2013/0150653         A1           2013/0158440         A1	<ul> <li>4/2011</li> <li>6/2011</li> <li>9/2011</li> <li>9/2011</li> <li>9/2011</li> <li>10/2011</li> <li>12/2011</li> <li>12/2012</li> <li>8/2012</li> <li>8/2012</li> <li>8/2012</li> <li>9/2012</li> <li>12/2012</li> <li>12/2013</li> <li>2/2013</li> <li>3/2013</li> <li>3/2013</li> <li>3/2013</li> <li>5/2013</li> <li>5/2013</li> <li>5/2013</li> <li>5/2013</li> <li>5/2013</li> <li>5/2013</li> <li>6/2013</li> <li>6/2013</li> <li>6/2013</li> </ul>	Marchitto et al. Shanks et al. Ron Edoute A61N 1/328 600/14 Manstein Allison et al. Levinson et al. Bratton Martens et al. Levinson Moses Gonzales et al. Brown et al. Burnett Muntermann A61N 2/004 600/9 Weyh et al. Susedik A61N 1/406 600/10 Levinson Rosen et al. Mueller et al. Levinson et al. Levinson et al. Levinson et al. Levinson et al. Levinson et al. Carsky et al. Zarsky et al. Zarsky et al. Zarsky et al. Zarsky et al. Borsody Allison
2011/0087312         A1           2011/0130618         A1           2011/0224761         A1           2011/0238050         A1           2011/0238050         A1           2011/0238050         A1           2011/0238050         A1           2011/0238051         A1           2011/023925         A1           2012/0053449         A1           2012/0197361         A1           2012/0239123         A1           2012/0302821         A1           2012/0310033         A1           2013/0030239         A1           2013/0066309         A1           2013/0066309         A1           2013/013127         A1           2013/013127         A1           2013/0123764         A1           2013/0123765         A1           2013/0123764         A1           2013/0131764         A1           2013/0131764         A1           2013/0150653         A1           2013/0150653         A1           2013/0158634         A1           2013/0158634         A1           2013/0158634         A1           2013/0158634	<ul> <li>4/2011</li> <li>6/2011</li> <li>9/2011</li> <li>9/2011</li> <li>9/2011</li> <li>9/2011</li> <li>10/2011</li> <li>12/2012</li> <li>8/2012</li> <li>8/2012</li> <li>8/2012</li> <li>8/2012</li> <li>11/2012</li> <li>12/2012</li> <li>12/2013</li> <li>3/2013</li> <li>3/2013</li> <li>3/2013</li> <li>3/2013</li> <li>5/2013</li> <li>5/2013</li> <li>5/2013</li> <li>5/2013</li> <li>5/2013</li> <li>6/2013</li> <li>6/2013</li> <li>6/2013</li> <li>6/2013</li> <li>6/2013</li> </ul>	Marchitto et al.Shanks et al.Ron EdouteRon Edoute $600/14$ MansteinAllison et al.Levinson et al.BrattonMartens et al.LevinsonMosesGonzales et al.Brown et al.BurnettMuntermannMueller et al.EvinsonRosen et al.BurnettMueller et al.LevinsonRosen et al.Levinson et al.Levinson et al.Zarsky et al.Zarsky et al.Zarsky et al.Zarsky et al.GrovePhillipsPhillipsAd1N 2/02600/14BorsodyAd1isonEdouteTing et al.
2011/0087312         A1           2011/0130618         A1           2011/0224761         A1           2011/0238050         A1           2011/0238050         A1           2011/0238050         A1           2011/0238050         A1           2011/0238050         A1           2011/023925         A1           2012/0053449         A1           2012/0197361         A1           2012/0239123         A1           2012/0302821         A1           2012/0310033         A1           2013/0030239         A1           2013/0066309         A1           2013/0079684         A1           2013/013127         A1           2013/013127         A1           2013/0123764         A1           2013/0123764         A1           2013/0123764         A1           2013/0131764         A1           2013/0131764         A1           2013/0130150653         A1           2013/0150653         A1           2013/0158634         A1	<ul> <li>4/2011</li> <li>6/2011</li> <li>9/2011</li> <li>9/2011</li> <li>9/2011</li> <li>9/2011</li> <li>10/2011</li> <li>12/2011</li> <li>12/2012</li> <li>8/2012</li> <li>8/2012</li> <li>8/2012</li> <li>11/2012</li> <li>12/2012</li> <li>12/2013</li> <li>2/2013</li> <li>3/2013</li> <li>3/2013</li> <li>3/2013</li> <li>5/2013</li> <li>5/2013</li> <li>5/2013</li> <li>5/2013</li> <li>5/2013</li> <li>6/2013</li> <li>6/2013</li> <li>6/2013</li> <li>6/2013</li> </ul>	Marchitto et al. Shanks et al. Ron Edoute A61N 1/328 600/14 Manstein Allison et al. Levinson et al. Bratton Martens et al. Levinson Moses Gonzales et al. Brown et al. Burnett Muntermann A61N 2/004 600/9 Weyh et al. Susedik A61N 1/406 600/10 Levinson Rosen et al. Mueller et al. Levinson et al. Levinson et al. Levinson et al. Zarsky et al. Zarsky et al. Zarsky et al. Zarsky et al. Borsody Allison Edoute

2013/0238061 A1	9/2013	Edoute
2013/0245731 A1	9/2013	Allison
2013/0253384 A1	9/2013	Anderson et al.
2013/0253493 A1	9/2013	Anderson et al.
2013/0253494 A1	9/2013	Anderson et al.
2013/0253495 A1	9/2013	Anderson et al.
2013/0253496 A1 2013/0317281 A1	9/2013 11/2013	Anderson et al. Schneider
2013/031/281 AI 2013/0331637 AI*	12/2013	Greff A61N 1/40
2015/0551057 711	12/2015	600/15
2014/0005760 A1	1/2014	Levinson et al.
2014/0018767 A1	1/2014	Harris et al.
2014/0025033 A1	1/2014	Mirkov et al.
2014/0046423 A1	2/2014	Rajguru
2014/0067025 A1	3/2014	Levinson et al.
2014/0081359 A1	3/2014	Sand
2014/0148870 A1	5/2014	Burnett
2014/0257443 A1 2014/0277219 A1	9/2014 9/2014	Baker et al. Nanda
2014/0277302 A1	9/2014	Weber et al.
2014/02/7502 A1	10/2014	Anderson et al.
2014/0303697 A1	10/2014	Anderson et al.
2014/0316393 A1	10/2014	Levinson
2014/0330067 A1	11/2014	Jordan
2014/0364841 A1	12/2014	Kornstein
2014/0371515 A1*	12/2014	John A61N 1/3605
		600/13
2015/0025299 A1	1/2015	Edoute
2015/0080769 A1	3/2015	Lotsch
2015/0088105 A1 2015/0112412 A1	3/2015 4/2015	Fatemi Anderson et al.
2015/0112412 A1 2015/0119849 A1	4/2015	Aronhalt et al.
2015/0123661 A1	5/2015	Yui
2015/0127075 A1	5/2015	Ward et al.
2015/0133717 A1	5/2015	Ghiron
2015/0157873 A1*	6/2015	Sokolowski A61N 2/02
		600/14
2015/0165232 A1	6/2015	Altshuler et al.
2015/0216719 A1	8/2015	DeBenedictis et al.
2015/0216720 A1 2015/0216816 A1	8/2015 8/2015	Debenedictis et al. O'Neil et al.
2015/0223975 A1	8/2015	Anderson et al.
2015/02223776 A1	10/2015	Gonzales et al.
2015/0297909 A1	10/2015	Peashock
2015/0328077 A1	11/2015	Levinson
2015/0328475 A1	11/2015	Kim et al.
2015/0342780 A1	12/2015	Levinson et al.
2015/0367141 A1	12/2015	Goetz
2016/0030763 A1	2/2016	Midorikawa et al.
2016/0051401 A1 2016/0051827 A1	2/2016 2/2016	Yee et al. Edoute
2016/0066994 A1	3/2016	Shanks
2016/0089550 A1	3/2016	Debenedictis et al.
2016/0175193 A1	6/2016	Jung
2016/0250494 A1	9/2016	Sakaki et al.
2016/0270951 A1	9/2016	Martins et al.
2016/0317346 A1	11/2016	Kovach
2016/0317827 A1	11/2016	Schwarz et al.
2016/0324684 A1 2016/0354237 A1	11/2016	Levinson et al.
2016/0354237 A1 2017/0001024 A1	12/2016 1/2017	Gonzales et al. Prouza
2017/0001024 A1	1/2017	Schwarz et al.
2017/0001026 A1	1/2017	Schwarz et al.
2017/0001027 A1	1/2017	Ladman et al.
2017/0001028 A1	1/2017	Ladman et al.
2017/0001029 A1	1/2017	Pribula et al.
2017/0001030 A1	1/2017	Pribula et al.
2017/0007309 A1	1/2017	Debenedictis et al.
2017/0072212 A1	3/2017	Ladman et al. Francincas
2017/0105869 A1 2017/0106201 A1	4/2017 4/2017	Frangineas, Jr. Schwarz et al.
2017/0100201 A1 2017/0120067 A1	4/2017 5/2017	Prouza
2017/0120007 A1	6/2017	Harris et al.
2017/0173347 A1	6/2017	Schwarz et al.
2017/0182334 A1	6/2017	Altshuler et al.
2017/0182335 A1	6/2017	Altshuler et al.
2017/0196731 A1	7/2017	Debenedictis et al.
2017/0239079 A1	8/2017	Root et al.
2017/0319378 A1	11/2017	Anderson et al.

#### (56) **References Cited**

#### U.S. PATENT DOCUMENTS

2017/0325992 A1	11/2017	Debenedictis et al
2017/0325993 A1	11/2017	Jimenez et al.
2017/0326042 A1	11/2017	Zeng et al.
2017/0326346 A1	11/2017	Jimenez et al.
2017/0348143 A1	12/2017	Rosen et al.
2018/0001106 A1	1/2018	Schwarz
2018/0001107 A1	1/2018	Schwarz et al.
2018/0125416 A1	5/2018	Schwarz et al.
2018/0153736 A1	6/2018	Mills et al.
2018/0153760 A1	6/2018	Rosen et al.
2018/0161197 A1	6/2018	Baker et al.
2018/0185081 A1	7/2018	O'Neil et al.
2018/0185189 A1	7/2018	Weber et al.
2018/0214300 A1	8/2018	Anderson et al.
2018/0228646 A1	8/2018	Gonzales et al.
2018/0236254 A1	8/2018	Schwarz et al.
2018/0250056 A1	9/2018	Avram et al.
2018/0263677 A1	9/2018	Hilton et al.
2018/0271767 A1	9/2018	Jimenez et al.
2018/0310950 A1	11/2018	Yee et al.
2019/0000524 A1	1/2019	Rosen et al.
2019/0000663 A1	1/2019	Anderson et al.
2019/0029876 A1	1/2019	Anderson et al.
2019/0053941 A1	2/2019	Samson

#### FOREIGN PATENT DOCUMENTS

AU	2014203094 B2	7/2015
AU	2013207657 B2	11/2015
CA	2604112 C	7/2016
CA	3019140 A1	10/2017
CA	3023821 A1	11/2017
CN	201906360 U	7/2011
CN	102319141 A	1/2012
CN	102319141 B	8/2014
CN	107613914 A	1/2018
CN	108882992 A	11/2018
CN	109310516 A	2/2019
DE	1118902 B	12/1961
DE	3205048 A1	8/1983
DE	3610474 A1	10/1986
DE DE	69318706 T2	1/1980
	0633008 T3	3/1999
DK		
EP	0209246 A1	1/1987
EP	0209246 A1	1/1987
EP	0459401 A1	12/1991
EP	0633008 A1	1/1995
EP	0633008 B1	5/1998
EP	1917935 B1	1/2011
EP	2676700 A2	12/2013
EP	2749259 A1	7/2014
EP	2856986 A1	4/2015
EP	3342379 A1	7/2018
ES	2118925 T3	10/1998
ES	2300569 T3	6/2008
ES	2359581 T3	5/2011
ES	2533145 A2	4/2015
ES	2533145 B1	7/2016
ES	2533145 R1	10/2018
FR	3041881 A1	4/2017
FR	3061012 A1	6/2018
GB	2286660 A	8/1995
GR	3027678 T3	11/1998
JP	2006130055 A	5/2006
JP JP	4324673 B2	9/2009
JP	2010533054 A	10/2010
JP	2017518857 A	7/2017
KR	20175100379 A	9/2015
KR	101650155 B1	8/2015
KR	20170107603 A	9/2010
KR	101794269 B1	9/2017
KR	20190005981 A	1/2017
KK MX		
	2012012158 A	4/2014
WO	WO-0044346 A1	8/2000
WO	2002025675 A1	3/2002

WO	WO-03078596 A2	9/2003
WO	2003090863 A1	11/2003
WO	WO-03103769 A1	12/2003
WO	2004087255 A1	10/2004
WO	2008109058 A1	9/2008
WO	WO-2009011708 A1	1/2009
WO	2010007614 A3	1/2010
WO	2010135425 A1	11/2010
WÕ	WO-2013026393 A1	2/2013
WO	WO-2013191699 A1	12/2013
WO	WO-2014109653 A1	7/2014
WO	2015012672 A1	1/2015
WO	WO-2015137733 A1	9/2015
WO	WO-2015179571 A1	11/2015
WO	WO-2017159959 A1	9/2017
WO	WO-2017176621 A1	10/2017
WO	WO-2017196548 A1	11/2017
WO	WO-2018044825 A1	3/2018
WO	WO-2018121998 A2	7/2018
WO	WO-2018122535 A1	7/2018
WŐ	WO-2017160097 A3	9/2018

### OTHER PUBLICATIONS

United States Patent and Trademark Office, Non-Final Office Action issued in U.S. Appl. No. 15/473,390 (dated Jun. 23, 2017).

Polk, "Therapeutic Applications of Low-Frequency Sinusoidal and Pulsed Electric and Magnetic Fields," The Biomedical Engineering Handbook, vol. 1, 2000, Second edition, pp. 1625-1636.

European Patent Office, International Search Report and Written Opinion for International Application No. PCT/IB2016/053930; dated Dec. 12, 2016; 19 pages.

Abulhasan, J.F., et al., "Peripheral Electrical and Magnetic Stimulation to Augment Resistance Training," Journal of Functional Morphology and Kinesiology, 1(3):328-342, (Sep. 2016).

Accent Radiofrequency System, Operator's Manual, Alma Lasers, Wellbeing Through Technology, 2008, 82 Pages.

Avram, M.M and Harry, R.S., "Cryolipolysis for Subcutaneous Fat Layer Reduction," Lasers in Surgery and Medicine, 41(10):703-708, Wiley-Liss, United States (Dec. 2009).

Bachasson, D., et al., "Quadriceps Function Assessment Using an Incremental Test and Magnetic Neurostimulation: a Reliability Study," Journal of Electromyography and Kinesiology, 23(3):649-658, Elsevier, England, (Jun. 2013).

Barker, A.T, "An Introduction to the Basic Principles of Magnetic Nerve Stimulation," Journal of Clinical Neurophysiology, 8(1):26-37, Lippincott Williams & Wilkins, United States, (Jan. 1991).

Behrens, M., et al., "Repetitive Peripheral Magnetic Stimulation (15 Hz RPMS) of the Human Soleus Muscle did not Affect Spinal Excitability," Journal of Sports Science and Medicine, 10(1):39-44, Dept. of Sports Medicine, Medical Faculty of Uludag University, Turkey (Mar. 2011).

Beilin, G., et al., "Electromagnetic Fields Applied to the Reduction of Abdominal Obesity," Journal of Cosmetic & Laser Therapy, 14(1):24-42, Informa Healthcare, England, (Feb. 2012).

Buenos Aires, Oct. 14, 2014, Venus Concept, Provision No. 7246, 56 pages (With Machine Translation).

Burge, S.M and Dawber, R.P., "Hair Follicle Destruction and Regeneration in Guinea Pig Skin After Cutaneous Freeze Injury," Cryobiology, 27(2):153-163, Elsevier, Netherlands (Apr. 1990).

Bustamante, V., et al., "Muscle Training With Repetitive Magnetic Stimulation of the Quadriceps in Severe COPD Patients," Respiratory Medicine, 104(2):237-245, Elsevier, England, (Feb. 2010).

Bustamante, V., et al., "Redox Balance Following Magnetic Stimulation Training in the Quadriceps of Patients With Severe COPD," Free Radical Research, 42(11-12):939-948, Informa Healthcare, England, (Nov. 2008).

Caress, J.B., et al., "A Novel Method of Inducing Muscle Cramps Using Repetitive Magnetic Stimulation," Muscle Nerve, 23(1):126-128, John Wiley & Sons, United States, (Jan. 2000).

Chesterton, L.S., et al., "Skin Temperature Response to Cryotherapy," Archives of Physical Medicine and Rehabilitation, 83(4):543-549, W.B. Saunders, United States (Apr. 2002).

#### (56) **References Cited**

### OTHER PUBLICATIONS

Course in Physical Therapy, Presentation, Jan. 4, 2013, 156 pages. CR Technology, Salus-Talent, Technical File of Electro-magnetic Stimulator, Document No. TF-005, 2008, 241 pages.

CR Technology, Technology for Health and Business for Human Being, investor relations, 2008, 21 pages.

CynoSure, SculpSure TM, The New Shape of Energy-Based body Contouring, 2015, Cynosure Inc, 2 pages.

Cynosure, Smooth Shapes XV, Now with Smoothshape petite, Transforming non-invasive Body Shaping, Retrieved from the Internet: (http://www.cynosure.com), 2011, Cynosure Inc, 8 pages.

DuoMAG Magnetic Stimulator, Alien Technik User Manuel, Jun. 26, 2012, 48 pages, Version 2.1.

Dybek, T., et al., "Impact of 10 Sessions of Whole Body Cryostimulation on Aerobic and Anaerobic Capacity and on Selected Blood Count Parameters," Biology of Sport, 29(1):39-43 (Jan. 2012).

Effective PEMF Magnetic Fat Reduction Slimming Body Beauty Salon Machine (PEMF Star), Wolfbeauty 1980, PEMF STAR, China, Retrieved from the Internet: (URL: https://www.ec21.com/ product-details/Effective-PEMF-Magnetic-Fat-Reduction—8928746. html), 2019, 5 pages.

Eliminate Stubborn Fat without Surgery or Downtime and Feel Great From Every Angle, Fear No Mirror®, Consultation Guide, Coolsculpting, 2014, 20 pages.

Exilis, Operators Manual, BTL, 2012, 44 Pages.

Goetz, S.M., et al., "Coil Design for Neuromuscular Magnetic Stimulation Based on a Detailed 3-D Thigh Model," IEEE Transactions on Magnetics, 50(6):10, IEEE, (Jun. 2014).

Gorodnichev, R.M., "Magnetic Stimulation of Muscles as New Method to Enhance Their Strength," Velikie Luki State Academy of Physical Culture and Sport, Velikie Luki, 2016, 5 pages.

Hamnegard, C.H., et al., "Quadriceps Strength Assessed by Magnetic Stimulation of the Femoral Nerve in Normal Subjects," Clinical Physiology and Functional Imaging, 24(5):276-280, Blackwell, England, (Sep. 2004).

Han, T.R., et al., "Magnetic Stimulation of the Quadriceps Femoris Muscle: Comparison of Pain With Electrical Stimulation," American Journal of Physical Medicine & Rehabilitation, 85(7):593-599, Lippincott Williams & Wilkins, United States, (Jul. 2006).

Hirvonen, H.E., et al., "Effectiveness of Different Cryotherapies on Pain and Disease Activity in Active Rheumatoid Arthritis. A Randomised Single Blinded Controlled Trial," Clinical and Experimental Rheumatology, 24(3):295-301, Clinical and Experimental Rheumatology S.A. S, Italy (May-Jun. 2006).

I-Lipo by Chromo genex, i-Lipo Ultra is the Intelligent, Non-Surgical Alternative to Liposuction, 2011, 2 pages.

Increasing Physiotherapy Presence in Cosmetology, Spa Inspirations, Jan. 2012, pp. 34-35.

Iskra Medical, Magneto System, 2012, 2 pages.

Jutte, L.S., et al., "The Relationship Between Intramuscular Temperature, Skin Temperature, and Adipose Thickness During Cryotherapy and Rewarming," Archives of Physical Medicine and Rehabilitation, 82(6):845-850, W.B. Saunders, United States (Jun. 2001).

Katuscakova, Z.L., et al., High Induction Magnet Therapy in Rehabilitation, Department of Physiactric Rehabilitation, 2012, 72 pages.

Kim, Y.H., et al., "The Effect of Cold Air Application on Intra-Articular and Skin Temperatures in the Knee," Yonsei Medical Journal, 43(5):621-626, Yonsei University, Korea (South) (Oct. 2002).

Korman, P., et al., "Temperature Changes in Rheumatoid Hand Treated With Nitrogen Vapors and Cold Air," Rheumatology International, 32(10):2987-2992, Springer International, Germany (Oct. 2012).

Lampropoulou, S.I., et al., "Magnetic Versus Electrical Stimulation in the Interpolation Twitch Technique of Elbow Flexors," Journal of Sports Science and Medicine, 11(4):709-718, Dept. of Sports Medicine, Medical Faculty of Uludag University, Turkey (Dec. 2012). Letter from Department of Health and Human Services, Public Health Service, Dec. 19, 2014, 7 pages. Lin, V.W., et al., "Functional Magnetic Stimulation for Restoring Cough in Patients With Tetraplegia," Archives of Physical Medicine and Rehabilitation, 79(5):517-522, W.B. Saunders, United States, (May 1998).

Lin, V.W., et al., "Functional Magnetic Stimulation of Expiratory Muscles: a Noninvasive and New Method for Restoring Cough," Journal of Applied Physiology (1985), 84(4):1144-1150, American Physiological Society, United States, (Apr. 1998).

Madariaga, V.B., et al., "[Magnetic Stimulation of the Quadriceps: Analysis of 2 Stimulators Used for Diagnostic and Therapeutic Applications]," Archivos De Bronconeumologia, 43(7):411- 417, Elsevier Espana, Spain, (Jul. 2007).

Mag Venture, Magnetic Stimulation, Accessories Catalogue, Accessories Catalogue, 2011, 54 pages.

MagVenture, MagPro® by MagVenture®, Versatility in Magnetic Stimulation, World Leading Transcranial Magnetic Stimulation Systems, 2011, 6 Pages.

Manstein, D., et al., "Selective Cryolysis: A Novel Method of Non-Invasive Fat Removal," Lasers in Surgery and Medicine, 40(9):595-604, Wiley-Liss, United States (Nov. 2008).

MecoTec Freezing Technology, Presentation Cryoair Whole Body Cryotherapy Chambers, Germany, Jul. 2017, 52 Pages.

Nadler, S.F., et al., "The Physiologic Basis and Clinical Applications of Cryotherapy and Thermotherapy for the Pain Practitioner," Pain Physician, 7(3):395-399, American Society of Interventional Pain Physicians, United States (Jul. 2004).

Nassab, R., "The Evidence Behind Noninvasive Body Contouring Devices," Aesthetic Surgery Journal, 35(3):279-293, Oxford University Press, England (Mar. 2015).

Neuro Star, TMS Therapy, Bringing Hope to Patients with Depression, 2013, 6 Pages.

Neurosoft, Ivanovo, Since 1992, Magnetic Stimulator, Neuro-MS, Technical Manual, Neurosoft Ltd, Ivanovo, Russia, 2006, 67 Pages. Nexstim NBS System, Navigated Brain Stimulation, Noninvasive, direct cortical mapping, 2012, 5 Pages.

Obsluze, N.K., Usage Instructions, User's Manual, Device for highinduction magnetic stimulation of type designation: Saluter Moti, 2016, 88 Pages.

Operating Manual: Magstim D70<sup>2</sup> Coil, MOP06-EN, Revision 01, The Magstim Company Limited, Feb. 2012, 14 Pages.

Operating Manual: Magstim Magstim 200<sup>2</sup>, MOP01-EN, Revision 01, The Magstim Company Limited, Sep. 2011, 25 Pages.

Operating Manual: Magstim, Magstim Alpha Coil Range, MOP11-EN, Revision 01, Oct. 2012, 18 Pages.

Operating Manual: Magstim, Magstim Bistim<sup>2</sup>, MOP02-EN, Revision, The Magstim Company Limited, 01, Sep. 2011, 27 Pages.

Operating Manual, Magstim, Model 200, P/N. 3001-01, Double 70mm, Remote Coil, P/N. 3190-00, The Magstim Company Limited, 2006, 32 Pages.

Operating Manual: Magstim R, 2nd, Generation Coil Family, 3100-23-02, Magstim Coils, The Magstim Company Limited, Nov. 2002, 14 Pages.

Operating Manual, Magstim R Air-Cooled Double 70mm Coil System, 1600-23-04, The Magstim Company Limited, 1999, 18 Pages.

Operating Manual: Magstim R, Bistim System, P/N. 3234-23-01, The Magstim Company Limited, Nov. 2004, 30 Pages.

Operating Manual: Magstim R, Coils & Accessories, 1623-23-07, Magstim Coils & Accessories, May 2010, 24 Pages.

Operating Manual: Magstim, RAPID2, P/N. 3576-23-09, The Magstim Company Ltd, Nov. 2009, 61 Pages.

Operator'S Manual: BTL Emsculpt, BTL Industries Ltd, United Kingdom, 2018, 35 pages.

Operator'S Manual: BTL, HPM-6000U, BTL Industries Ltd, United Kingdom, Dec. 2016, 36 pages.

Otte, J.S., et al., "Subcutaneous Adipose Tissue Thickness Alters Cooling Time During Cryotherapy," Archives of Physical Medicine and Rehabilitation, 83(11):1501-1505, W.B. Saunders, United States (Nov. 2002).

Papimi, For Scientific Research, Pap Ion Magnetic Inductor, Presentation, Magnetotherapeutic Device, Nov. 2009, 61 Pages.

Podebradsky.K., et al., Clinical study of high-inductive electromagnetic stimulator Salus talent, 2010, 8 pages.

#### (56) **References Cited**

### OTHER PUBLICATIONS

Polkey M.I., et al., "Functional Magnetic Stimulation of the Abdominal Muscles in Humans," American Journal of Respiratory and Critical Care Medicine, 160(2):513-522, American Thoracic Society, United States (Aug. 1999).

Polkey, M.I., et al., "Quadriceps Strength and Fatigue Assessed by Magnetic Stimulation of the Femoral Nerve in Man," Muscle Nerve, 19(5):549-555, John Wiley & Sons, United States, (May 1996).

Quick Start Manuals, Magstim Super Rapid Plus Quick Start, Aalto TMS Laboratory, Aalto School of Science, 2013, 7 Pages.

Reaction User Manual, Viora, Doc No. MK-004 A, 2008, 53 Pages. Reshaping the Future of Your Practice, Cool sculpting, A Revolution in Aesthetic Fat Reduction, 2011,10 Pages.

Salus Talent-A, Remed, User Guide, High Intensity Electro Magnetic Field Therapy, 2017, 37 pages.

Szecsi, J., et al., "A Comparison of Functional Electrical and Magnetic Stimulation for Propelled Cycling of Paretic Patients," Archives of Physical Medicine and Rehabilitation, 90(4):564-570, W.B. Saunders, United States, (Apr. 2009).

Szecsi, J., et al., "Force-pain Relationship in Functional Magnetic and Electrical Stimulation of Subjects With Paresis and Preserved Sensation," Clinical Neurophysiology, 121(9):1589-1597, Elsevier, Netherlands, (Sep. 2010).

Taylor, J.L, "Magnetic Muscle Stimulation Produces Fatigue Without Effort," Journal of Applied Physiology (1985), 103(3):733-734, American Physiological Society, United States, (Sep. 2007).

Tesla Stym, Iskra Medical, Tone the inner muscle with FMS Functional Magnetic Stimulation, 2013, 4 pages.

Ultra Slim Professional, The very best body Contouring, Wardphotonics LLC, 2018, 16 pages. User Guide: Mag Venture, Magpro family, MagPro R30, MagPro R30 with MagOption, MagPro X100, MagPro X100 with MagOption, MagPro software v.5.0, US-edition, MagPro family User Guide, 2010, 52 Pages.

User Guide, Salus Talent Pro, REMED, High Intensity Electro magnetic Field Therapy-2 Channel, 2017, Version M-1.0.0, 45 pages.

User Guide, Salus Talent, REMED, High Intensity Electro magnetic Field Therapy, Version. M-1.0.0, 2017, 40 pages.

User'S Manual: BTL-6000, Super Inductive System Elite, BBTL Industries Ltd, United Kingdom, Sep. 2016, 36 pages.

User Manual: Electro-magnetic Stimulator, Salus-Talent, Version 1.00, Rehabilitation Medical Company, 2013, 34 Pages.

User Manual: Regenetron Pro, System Information, Regenetron Pro User Manual, Nov. 2014, 7 Pages.

Vanquish Operator's Manual, BTL, 2012, 48 Pages.

Venus Legacy, User Manual International, 2009, Venus Concept, 49 pages.

Verges S., et al., "Comparison of Electrical and Magnetic Stimulations to Assess Quadriceps Muscle Function," Journal of Applied Physiology (1985), 106(2):701-710, American Physiological Society, United States, (Feb. 2009).

Wasilewski, M.L., Academy of Aesthetic and Anti-Aging Medicine, Application of magnetic fields with deep stimulation in the fight against local obesity of lower limbs, BTL, 2012, 11 pages.


Web MD, what is normal body temperature? 3 pages, printed Mar. 4, 2019.

Zelickson, B., et al., "Cryolipolysis for Noninvasive Fat Cell Destruction: Initial Results From a Pig Model," Dermatologic Surgery, 35(10):1462-1470, Hagerstown, MD Lippincott, Williams & Wilkins, United States (Oct. 2009).


Zeltiq System User Manual—Print and Binding Specifications, ZELTIQ Aesthetics, Inc, Mar. 2011. 88 pages.

Zerona R-Z6 by Erchonia, Specifications, Retrieved from the Internet: (http://www.myzerona.com), 2015, 1 page.


\* cited by examiner

















Figure 4A









Figure 5






Figure 7A




Figure 7B

10

# **AESTHETIC METHOD OF BIOLOGICAL** STRUCTURE TREATMENT BY MAGNETIC FIELD

# PRIORITY CLAIM

This application claims priority to U.S. Provisional Patent Application Nos. 62/357,679 filed Jul. 1, 2016, 62/440,905 filed Dec. 30, 2016, and 62/440,922 filed Dec. 30, 2016. These applications are incorporated herein by reference.

# FIELD OF THE INVENTION

The present invention generally relates to methods using the influence of magnetic and induced electric field on 15 biological structure. The magnetic field is time-varying and high powered therefore the method is based on a value of magnetic flux density sufficient to induce at least partial muscle contraction.

### BACKGROUND OF THE INVENTION

Aesthetic medicine includes all treatments resulting in enhancing a visual appearance and satisfaction of the patient. Patients want to minimize all imperfections includ- 25 ing body shape and effects of natural aging. Indeed, patients request quick, non-invasive procedures providing satisfactory results with minimal risks.

The most common methods used for non-invasive aesthetic applications are based on application of mechanical 30 waves, e.g. ultrasound or shock wave therapy; or electromagnetic waves, e.g. radiofrequency treatment or light treatment, such as intense pulsed light or laser treatment. The effect of mechanical waves on tissue is based especially on cavitation, vibration and/or heat inducing effects. The effect 35 of applications using electromagnetic waves is based especially on heat production in the biological structure.

Skin tissue is composed of three basic elements: epidermis, dermis and hypodermis or so called subcutis. The outer and also the thinnest layer of skin is the epidermis. The 40 for focused remodeling of the patient's body. The coil of the dermis consists of collagen, elastic tissue and reticular fibers. The hypodermis is the lowest layer of the skin and contains hair follicle roots, lymphatic vessels, collagen tissue, nerves and also fat forming a subcutaneous white adipose tissue (SWAT). The adipose cells create lobules 45 which are bounded by connective tissue, fibrous septa (retinaculum cutis).

Another part of adipose tissue, so called visceral fat, is located in the peritoneal cavity and forms visceral white adipose tissue (VWAT) located between parietal peritoneum 50 and visceral peritoneum, closely below muscle fibers adjoining the hypodermis layer.

Existing devices have low efficiency and they waste energy, which limits their use. Eddy currents induced within the coil create engineering challenges. Existing devices 55 higher repetition rates and the contraction is stronger. Therecontain coils which are made of metallic strips, electric wires or hollow conductors. Since the therapy requires large currents, significant losses are caused by induced eddy currents within the coil. Eddy currents lead to production of unwanted heat and therefore there is need to sufficiently cool 60 the coil. Also, the energy source must be protected during reverse polarity of resonance. This requires using protective circuits which consume significant amounts of energy.

Current magnetic aesthetic methods are limited in key parameters which are repetition rate and/or magnetic flux 65 density. All known methods use low values of magnetic flux density and/or low repetition rates which does not allow

satisfactory enhancement of visual appearance. As a result, new methods are needed to enhance the visual appearance of the patient.

The currently used aesthetic applications don't provide any treatment combining the effect of time-varying magnetic field treatment and conventional treatment, e.g. treatment by electromagnetic field such as radiofrequency treatment. The currently used radiofrequency treatment includes many adverse events such as non-homogenous thermal temperature, insufficient blood and/or lymph flow during and/or after the treatment. Additionally several adverse event such as panniculitis may occur after the treatment.

# SUMMARY OF THE INVENTION

The present methods and devices as described below produce a time varying magnetic field for patient treatment which better optimizes energy use, increases the effectiveness of the treatments and provide a new treatment. The 20 magnetic pulses may be generated in monophasic, biphasic or polyphasic regimes. In a first aspect, the device has one or more coils; a switch; an energy storage device and a connection to an energy source. The coil may be made of insulated wires with a conductor diameter less than 3 mm even more preferably less than 0.5 mm and most preferably less than 0.05 mm. Smaller diameter and individual insulation of the wires significantly reduces self-heating of the coil and therefore increase efficiency of magnetic stimulation device. The coil may be flexibly attached in a casing of device. The casing may comprise a blower or blowers which ensure cooling of the coil.

Using a plurality of magnetic field generating devices provides faster treatment. Large and/or different areas may be treated in shorter time. Using a plurality of applicators allows different areas and/or target biological structures to be stimulated at the same time. The movement of the at least one applicator may automatically follow a predetermined trajectory. Hence manual manipulation is not needed.

The present methods provide new aesthetic applications magnetic stimulation device may be flexibly attached to casing of the device. The blower or blowers may be arranged to blow air on both sides of coil. Optionally, the coil may be a flat type coil.

The method of treating a biological structure uses a combination of non-invasive methods for enhancing human appearance. The invention utilizes electromagnetic field. Methods may be used for targeted remodeling of adipose tissue, focused treatment of cellulite, body contouring, skin tightening or skin rejuvenation. The invention relates to focused heating of the target tissue by electromagnetic waves, whereas the effect of focused heating of the target tissue is amplified by the effect of a magnetic treatment.

The magnetic treatment induces the muscle contraction at fore the treatment is more efficient for reducing the number and/or volume of adipocytes and enhancing the visual appearance of the treated body region via targeted muscle contraction. Further the temperature homogeneity of is improved. Additionally, strong muscle contractions at higher repetition rates cause mechanical movement of all the layers in proximity of the contracted muscle. The methods therefore cause remodeling and/or neogenesis of the collagen and elastin fibers.

The methods enable new treatments by magnetic and/or electromagnetic field. The repetition rate of the magnetic field is in the range of 1 to 300 Hz with high magnetic flux

20

30

50

60

65

density up to 7 Tesla (equivalent to 70000 Gauss). The frequency of the electromagnetic field is 13.56 or 40.68 or 27.12 MHz or 2.45 GHz.

#### Glossary

Conventional non-invasive and/or invasive aesthetic medicine treatment methods refer to aesthetic applications based on application of mechanical waves, e.g. acoustic wave, ultrasound or shock wave therapy; or electromagnetic waves, e.g. radiofrequency or diathermy treatment or light treatment, such as intense pulsed light or laser treatment; or mechanical stimulation, e.g. positive or negative pressure, rollerball, massage etc.; or thermal treatment, e.g. cryotherapy; or electrotherapy method; or mesotherapy method and or any combination thereof.

Thermal treatment refers to treatment by heating or cooling, e.g. a cryotherapy treatment.

Biological structure is at least one neuron, neuromuscular plate, muscle fiber, adipose cell or tissue, collagen, elastin, pigment or skin.

Remodeling target biological structure refers to reducing the number and/or volume of the adipocytes by apoptosis and/or necrosis, cellulite treatment, body shaping and/or contouring, muscle toning, skin tightening, collagen treatment, skin rejuvenation, wrinkle removing, reducing stretch-<sup>25</sup> marks, breast lifting, lip enhancement, treatment of vascular or pigmented lesions of the skin or hair removing.

Body region includes muscle or muscle group, buttocks, saddlebags, love handles, abdomen, hips, thighs, arms, limb and/or any other tissue.

Muscle includes at least one of muscle fiber, muscle tissue or group, neuromuscular plate or nerve innervating the at least one muscle fiber.

Deep muscle refers to a muscle that is at least partly below superficial muscles and/or to the muscle that is covered by <sup>35</sup> a thick layer of other tissue, e.g. mostly adipose tissue and/or the skin, with thickness 0.5, 1, 2, 3, 4, 5 or more centimeters.

Adipose tissue refers to at least one lipid rich cell, e.g. adipocyte.

Bolus refers to a layer of fluid material, e.g. water or fluid <sup>40</sup> solution of ceramic particles, preferably enclosed in a flexible sac made of biocompatible material.

Impulse refers to a single magnetic stimulus.

Pulse refers to a period of treatment by a magnetic field of at least one magnetic stimulus and time duration of no <sup>45</sup> stimulation, i.e. time duration between two impulses from rise/fall edge to next rise/fall edge.

Repetition rate refers to frequency of firing the pulses; it is derived from the time duration of a pulse.

# BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a cross section view of a coil winding.

FIG. 2 is a cross-section of a magnetic applicator.

FIG. **3** is a side view of a casing of a magnetic applicator. <sup>55</sup> FIGS. **4**A and **4**B illustrate circuits for providing high power pulses to a stimulating coil.

FIG. **5** is a graph showing voltage drop in the energy storage device.

FIG. 6 is a diagram of a biological effect.

FIGS. 7A and 7B illustrate diagrams of a treatment device.

#### DETAILED DESCRIPTION

FIG. 1 illustrates a cross section of winding of a coil for a magnetic stimulation device. The coil may be constructed from litz-wire, wherein each wire is insulated separately. Each individual conductor is coated with non-conductive material so the coil constitutes multiple insulated wires. Unlike existing magnetic coil conductors, the present coil is not made of bare wire e.g. litz-wire without insulation, or conductive tapes, conductive strips, or copper pipe with hollow inductors. The insulation of wires separately is a substantial improvement, since this leads to a significant reduction of the induced eddy currents. Power loss due to eddy currents, per single wire, is described by Equation 1 below. The small diameter of wires significantly reduces self-heating of the coil and therefore increases efficiency of the present magnetic stimulation device.

where:  $P_{EDDY}$  is power loss per unit mass (W·kg<sup>-1</sup>);  $B_p$  is the peak of magnetic field (T); f is frequency (Hz); d is the thickness of the sheet or diameter of the wire (m); k is constant equal to 1 for a thin sheet and 2 for a thin wire;  $\rho$ is the resistivity of material ( $\Omega$ ·m); D is the density of material (kg·m<sup>3</sup>).

The individual insulation of each wire reduces eddy currents. The individually insulated wires may be wound either one by one or in a bundle of individually insulated wires so as to form a coil, which will serve as a magnetic field generator. The coil provides an improvement in the efficiency of energy transfer in the LC resonant circuit and also reduces or eliminates unwanted thermal effects.

The coil may have a planar coil shape where the individually insulated wires may have cross-section wires with conductor diameter less than 3 mm even more preferably less than 0.5 mm and most preferably less than 0.05 mm. The wires are preferably made of materials with higher density and higher resistivity e.g. gold, platinum or copper. The diameters of the single wires should be minimal. On the other hand the total diameter should be maximal because of inverse proportion between the cross-section of all wires forming the coil and the electrical resistance. Therefore the ohmic part of the heat is then lower. Eq. 2 describes power loss of the coil:

$$P_R = \frac{\rho \cdot \frac{l}{S} \cdot l^2}{m}$$
 Eq. 2

Where:  $P_R$  is the power loss heat dissipation (W);  $\rho$  is the resistance ( $\Omega$ ·m); 1 is the length of wire (m); S is the surface area (m<sup>2</sup>); I is the current (A) and m is 1 kg of wire material. Total power loss is (Eq. 3):

$$T_{TOT} = P_{EDDY} + P_R,$$
 Eq. 3

Where:  $P_{TOT}$  is the total power losses (W·kg<sup>-1</sup>);  $P_{EDDT}$  is the power dissipation of eddy currents (W·kg<sup>-1</sup>);  $P_R$  is the power loss heat dissipation (W·kg<sup>-1</sup>).

Power losses and/or heat generation may be monitored and/or determined by the magnetic stimulation device based on determining the waveform of any operation parameter, e.g. voltage, electric current or magnetic flux density. The determined waveform is related with a reference and/or with the operation parameter measured in a different value of a characteristic quantity, e.g. time, frequency, amplitude or phase.

Dynamic forces produced by current pulses passing through the wires of the coil cause vibrations and unwanted noise. The individual insulated wires of the coil may be impregnated under pressure so as to eliminate air bubbles between the individual insulated wires. The space between 5 wires can be filled with suitable material which causes unification, preservation and electric insulation of the system. Suitable rigid impregnation materials like resin, and elastic materials like PTE can be also used. With the coil provided as a solid mass, the vibrations and resonance caused by movements of the individual insulated wires are suppressed. Therefore noise is reduced.

The coil may be attached to the case of the applicator, such as a hand held applicator of the magnetic stimulation 15 device; build-in applicator in e.g. chair, bed; or stand-alone applicator e.g. on mechanical fixture. The attachment may be provided by an elastic material e.g., silicone, gum; or other flexible manner. Connection with the coil of the applicator's case can be ensured by several points. The 20 several fastening points ensure the connection of the coil to the casing by flexible material so that the main part of the coil and the main part of the casing of applicator are spaced apart. The spacing should be at least 0.1 mm so that air can easily flow. The gap between the coil and the casing can be 25 used either for spontaneous or controlled cooling. The coil may optionally be connected to the case of the applicator by only one fastening point. The fastening points eliminate vibrations of wires which could be transferred to housing of the applicator and therefore reduce noise of the magnetic 30 stimulation device.

FIG. 2 is a cross-section of the magnetic applicator which allows better flow on the lower and upper sides of the coil and thus more efficient heat dissipation. The magnetic stimulation device includes a coil 1, the circuit wires 2 and 35 the fastening points 3 for connection of the coil to the casing of the applicator (not shown). The fastening points 3 are preferably made of flexible material however the rigid material may be used as well. The fastening points 3 may be located on the outer circumferential side of the coil. How- 40 ever, alternatively it is possible to put these fastening points to a lower or upper side of the coil.

The fastening points 3 connect the coil to the case of the applicator in at least one point. The fastening points 3 maintain the coil and the main part of the case of the 45 applicator spaced apart so that fluid (which may be air or any liquid) can flow between them. At least one blower 4 can be placed around the circumference of the coil, or perpendicular to the coil. The blower can be any known kind of device for directing the fluid e.g. outer air directed into the case of 50 the applicator. This arrangement of the blower allows air to bypass the coil from upper and lower (patient's) sides. In still another embodiment the outer air can be cooled before directing into the case. The blower can have an inlet placed around the circumference of the coil for injecting air, to 55 remove heat from the coil. A connecting tube (not shown) can ensure connection of the applicator 5 with the energy source and/or control unit of magnetic stimulation device. The connecting tube may also contain a conduit of the fluid.

The arrows 6 indicate the air flow through the applicator 60 5. This arrangement of the blower allows the air to bypass the coil from upper and lower (patient's) side. Outlet may be preferably placed on upper side of the casing. By placing the blower around the circumference of the coil instead of on the top/below the coil, the blower 4 does not interfere with the 65 magnetic flux peak and therefore its lifespan and reliability is increased.

6

FIG. 3 is an illustrative embodiment of a casing of the magnetic applicator. The overview drawing contains casing itself 7, which might contain an outlet 8 preferably placed on upper side of the casing 7. A connecting tube 9 may not only ensure connection of the applicator with the energy source and/or control unit of magnetic stimulation device, but also connection to a source of the fluid; however the conduit of the fluid 10 may also be connected separately.

In an alternative embodiment cooling may be provided by a member using thermoelectric effect, e.g. a Peltier cooler. Alternatively, cooling may be provided by Stirling engine cooling system.

FIG. 4A and FIG. 4B illustrate circuits for providing high power pulses to the stimulating coil. FIG. 4A shows a circuit for providing high power magnetic pulses. FIG. 4B shows a circuit for providing high power pulses.

The state of art magnetic stimulation device achieves magnetic flux density of a few tenths to several ones of Tesla (1 Tesla is equivalent to 10000 Gauss). To achieve this level of magnetic flux density, the energy source used generates sufficient voltage. This voltage can reach thousands of volts. In FIG. 4A the circuits for providing high power pulses to the stimulating coil contain a series connection to the switch 11 and the coil 12. The switch 11 and the coil 12 together are connected in parallel with an energy storage device 13. The energy storage device 13 is charged by the energy source 14 and the energy storage device 13 then discharges through the switching device 11 to the coil 12.

During second half-period of LC resonance, the polarity on the energy storage device 13 is reversed in comparison with the energy source 14. In this second half-period, there is a conflict between energy source 14, where voltage on positive and negative terminals is typically thousands of Volts. The energy storage device 13 is also charged to the positive and negative voltage generally to thousands of Volts. As a result, there is in the circuit, consequently, twice the voltage of the energy source 14. Hence the energy source 14 and all parts connected in the circuit are designed for a high voltage load. Therefore, the protective resistors and/or protection circuitry 15 must be placed between energy source 14 and energy storage device 13. Disadvantage of state of art solution is large amount of energy transformed to undesired heat in protective resistors and/or protection circuitry 15.

FIG. 4B shows a circuit for providing high power pulses for improved function of the magnet stimulation device. The coil 16 and an energy storage device 17 are connected in series and disposed in parallel to the switch 18. The energy storage device 17 is charged through the coil 16. To provide an energy pulse, controlled shorting of energy source 33 takes place through the switch 18. In this way the high voltage load at the terminals of the energy source 19 during the second half-period of LC resonance associated with known devices is avoided. The voltage on the terminals of energy source 19 during second half-period of LC resonance is a voltage equal to the voltage drop on the switch 18.

The switch 18 can be any kind of switch such as diode, MOSFET, JFET, IGBT, BJT, thyristor or their combination. Depending on the type of component the load of energy source 19 is reduced to a few Volts, e.g., 1-10 volts. Consequently, it is not necessary to protect the energy source **19** from a high voltage load, e.g., thousands of Volts. The use of protective resistors and/or protection circuits is reduced or eliminated. The present designs simplify the circuits used, increase efficiency of energy usage and provide higher safety.

The treatment by the magnetic stimulation device may be in different operation modes. One operation mode may generate a plurality of impulses at one time within the pulse. Another operation mode may generate a plurality of the impulses at different times within the pulse. Both operation 5 modes may be combined.

In an example, a magnetic stimulation device includes at least one energy source, N energy storage devices, N magnetic field generating devices, and 2×N switching devices, wherein N is a positive integer greater than 1. The at least 10 one energy storage device may be selectively charged by the energy source by selectively switching the switching devices and the impulses may be selectively generated by selectively switching the switching devices.

The magnetic stimulation device may include a plurality 15 of applicators. The applicator includes at least one magnetic field generating device which may be movable. The benefit of this embodiment is that the movement and/or positioning of the plurality of the applicators may be independent. Hence, different parts of the patient's body may be treated 20 simultaneously. Therefore, the total treatment time is reduced and patient's downwtimes are reduced as well. The movement of the at least one applicator may be automatic so that manual manipulation may not be needed. The movement of the at least one applicator may follow a predeter-25 mined trajectory or it may be random. In an alternative embodiment the movement of the plurality of applicators may be synchronized.

The plurality of applicators may be positioned with respect to each other in one plane; in at least two mutually 30 tilted planes defined by convex or concave angles, or perpendicular to each other; or in at least two parallel planes. The angles of the planes may be adjusted by an operator following the patient's needs. In an alternative embodiment the patient may be positioned in the intersection of the 35 magnetic fields generated by the plurality of magnetic field generating devices.

FIG. 5 shows an exponential voltage drop in the energy storage device. Energy savings during time-varying magnetic therapy may be characterized by reduced voltage drop 40 in the energy storage device between the first, second and subsequent maximums of the resonant oscillation. The magnitude of the individual voltage oscillations is exponentially dampened up to establishing the energy balance. This allows increasing the maximum possible frequency/repetition rate 45 of magnetic pulses, since the frequency/repetition rate is dependent on the speed with which it is possible to recharge the energy storage device. Since the energy storage device is recharged by the amount of energy loss during the previous pulse, it is possible to increase the frequency/repetition rate 50 of the device up to hundreds of magnetic pulses per second without the need to increase the input power. The voltage drop between any of the successive amplitudes is not higher than 21%, even more preferably not higher than 14% and most preferably not higher than 7%.

The device can be used for treatment/successive treatments in continual, interrupted or various duty cycle regime. The duty cycle may be higher than 10%, which means interrupted regime with the ratio up to 1 active to 9 passive time units. The ratio may possibly change during the 60 therapy. The device enables operation defined by the peak to peak magnetic flux density on the coil surface at least 3 T, more preferably at least 2.25 T, most preferably at least 1.5 T at repetition rates above 50 Hz, more preferably at repetition rates above 60 Hz, even more preferably at 65 repetition rates above 70, most preferably at repetition rates above 80 Hz with treatment/successive treatments lasting

several seconds or longer, for example, for at least 5, 10, 30, 60, 120 or 240 seconds, or longer. The total power consumption is below 1.3 kW and the width of pulses is in the range of hundreds of  $\mu$ s.

The device enables achieving repetition rates above 100 Hz, more preferably repetition rates above 150 Hz, most preferably repetition rates above 200 Hz with the magnetic flux density providing a therapeutic effect on neurons and/or muscle fibers and/or endocrine cells (e.g. at least partial muscle contraction, action potential in cell). Based on achievement of repetition rates in order of few hundreds the device also enables assembling the magnetic pulses into the various shapes (e.g. triangular, rectangular, exponential), with the shape widths from 6 ms to several seconds or longer.

Alternatively the magnetic field generating device may generate a static magnetic field. The magnetic field generating device generating the static magnetic field may be e.g. a permanent magnet or electromagnet. The coil may be powered by a power source, a transformer and/or an energy storage device. The magnetic field may be applied as timevarying magnetic field by movement of the magnetic field generating device. Alternatively the magnetic field generating device may be switched on and off.

According to the invention a current value of an operation parameter, e.g. voltage, electric current or magnetic flux density, may be determined by measuring via a suitable sensor or by deriving from a value of voltage source, e.g. an energy storage device or power source. The currently determined operation parameter is processed by a mathematic and/or signal processing method.

The currently measured voltage waveform and the calibration curve are related using a mathematic and/or signal processing method. Based on the relation at least one threshold may be established. The at least one threshold may correspond to the correctness of the stimulation and/or notify operator of the magnetic stimulation device about an unintended event. The unintended event may refer to detection of a metal object e.g. metal jewelry such as ring or bracelet, or a prosthetic device such as an endoprosthesis or surgical nail within the proximity of the magnetic stimulation device; or to detection of a hardware error of the magnetic stimulation device, e.g. error of the switching device such as a thyristor. Based on the evaluation of any unintended event the treatment may be disabled and/or the notification for the operator may be generated by the magnetic stimulation device in a human perceptible form, e.g. by mechanical and/or electromagnetic means, such as audibly perceptible notification (e.g. beep) or visually perceptible notification (flashing light, color change etc.).

According to another aspect of the application, the magnetic stimulation device may disable the treatment in the case that the temperature determined by the calculation algorithm exceeds the maximal temperature. In this case the 55 magnetic stimulation device may suggest at least one maximal value of treatment parameter. Based on the predicted temperature of the magnetic stimulation device the calculation algorithm may determine at least one value of treatment parameter to not exceed the maximal temperature of the magnetic stimulation device during the treatment. Based on the operator's preferences the value of the treatment parameter may be automatically adjusted by the magnetic stimulation device or it may be suggested to the operator in human perceptible form such as audibly perceptible notification (e.g. beep) and/or visually perceptible notification (e.g. flashing light, color change etc.). In an exemplary application the suggested treatment parameter may be a maximal

achievable value of magnetic flux density which can be sufficiently cooled by the cooling system. However, any other treatment parameter may be suggested to the operator.

During last few decades patient have not only wanted to be in good health, they have also wanted to look well, i.e. to 5 be well shaped, without any unattractive fat and to have a young appearance, without wrinkles, stretchmarks or sagging breasts. This has resulted in a progressive evolution of invasive aesthetic methods such as surgical removing of fat and remodeling the human body by invasive and potentially 10 dangerous methods, e.g. liposuction or inserting implants into human body. The side effects of invasive methods may be scars, swelling or bruising. The side effects resulted in the rapid progress in non-invasive method, e.g. lipolysis or removing skin imperfections. One example of the last few 15 years may is rapid increase of patients' demand for enhancing the visual appearance of buttocks. This has resulted in a higher percentage of these operations by plastic surgeons.

Electric current may be induced in the treated biological structure during pulsed magnetic treatment. Due to the high 20 value of magnetic flux density the biological structure may be targeted and treated more specifically. A distribution of magnetic field is uniform in the biological structure. Particles (e.g. atoms, ions, molecules etc.) in the biological structures are influenced by the magnetic field and perme-25 ability of a cell membrane may also increase.

Due to increased permeability of the cell membrane, the pulsed magnetic treatment may induce following effects: at least partial muscle contraction; reduction of adipose tissue—volume and/or number of the adipose cells; neogenesis 30 and/or remodeling of collagen and/or elastin fibers. Further magnetic treatment may improve circulation of blood and/or lymph and improve local and/or adipose tissue metabolism.

Motor-threshold stimulus is stimulation by magnetic flux density which induces sufficient current flow in the target 35 biological structure at a level to begin to cause at least partial muscle contraction.

With the present methods, factors for enhancing visual appearance of the body include: treatment of major muscle, e.g. gluteus maximus; treatment of deep muscle which may 40 be enabled by high value of magnetic flux density; non-contact application of magnetic flux density, it may be applied even through clothing; stronger muscle contraction due to higher value of magnetic flux density; higher-quality of muscle targeting; treatment may not be influenced by 45 small movements during treatment; treatment time duration may be shortened due to high value of magnetic flux density and/or higher repetition rate; no delays may occur.

It is to be understood that the method is not limited to the particular applications and that the method may be practiced 50 or carried out in various ways.

Present method may be applied for enhancing the visual appearance of body parts including or proximate to major muscle structures. Further the method may be applicable for enhancing the visual appearance of patients with high value 55 of BMI. A patient with BMI of at least 18, preferably at least 25, more preferably at least 30, most preferably at least 35 or more may be preferably treated by the recited methods. The thickness of patient's SWAT and/or VWAT may be at least 0.1, 0.5, 10, 15, 25, 50, 75, 100 or more. The patient 60 may be preferably healthy without any life-threatening conditions such as circulatory system disease, e.g. deep vein thrombosis. The present method is not limited to the application of the treatment to major muscle. Muscles other than major muscles may be treated as well. 65

The applicator of magnetic treatment may be placed proximate to the patient's body. As used here, proximate to includes both contactless and in actual contact with the skin of the patient. The muscles may be selectively treated and the magnetic flux density may be adjusted following the patient's feeling or needs. The treatment time may be shortened due to selective treatment of the correct muscles. Additionally, due to the high value of magnetic flux density, the muscle may be treated more effectively. Further, the treatment may be non-invasive or even preferably contactless due to the high value of magnetic flux density. The patient may be treated without removing clothing, reducing patient discomfort. Additionally, following the high efficiency of the muscle contraction the collagen and/or elastin fibers above the muscle structure may be remodeled, hence the visual appearance may be enhanced.

The position of the patient may correspond to treated biological structure and/or body region. The patient may be treated in seated position. Alternatively, the patient may be treated in lying position, e.g. in supine position. Treatment in lateral recumbent position may be also applicable. Patient may be in prone position as well.

In the preferred application the treatment method may be applied to body regions prone to cellulite and/or prone to adipose accumulation, such as thighs, saddlebags, buttocks, abdomen, region of love handles, region of bra fat or arm. The adipose accumulation may be influenced by number and/or volume of adipose cells.

The magnetic treatment of the biological structure may have various applications for enhancing visual appearance of the contour of a body region. High density magnetic field reaching such values which may be used for: adipose tissue reduction, wherein the adipose tissue reduction may be achieved by reduction of number and/or volume of adipose cells; muscle toning, wherein the muscle appearance enhancement may be achieved by adipose tissue reduction with no muscle bulking; muscle shaping, wherein the muscle appearance enhancement may be achieved by adipose tissue reduction and/or muscle bulking; body contouring, wherein the silhouette appearance enhancement may be achieved by adipose tissue reduction with no muscle bulking; body shaping, wherein the silhouette appearance enhancement may be achieved by adipose tissue reduction and/or muscle bulking; skin tightening, wherein the skin appearance enhancement may be achieved by obtaining smoother and younger appearance, including wrinkles reduction; cellulite treatment, wherein the appearance enhancement may be achieved by adipose tissue reduction, muscle contraction and/or elastic fibers neogenesis; circumferential reduction, wherein the reduction may be achieved by adipose tissue reduction and/or the muscle bulking; breast enhancement, wherein the appearance enhancement effect may be achieved by elevation or shape modification; lip enhancement, wherein the lip appearance enhancement may be achieved by obtaining fuller and firmer appearance. The body region may be reduced in overall size. Further aesthetic effects may be achieved, e.g. connective tissue improvement, fat disruption, muscle volumization, muscle forming, muscle toning, muscle remodeling, contouring, sculpting or body sculpting.

In the methods described, the magnetic stimulation device may or may not include a magnetic core. The magnetic stimulation device may be cooled by fluid, e.g. by air, water or oil. Total power consumption of the magnetic stimulation device may be below 1.3 kW. The power of the magnetic stimulation device may be at least 150, 250 or 500 W to generate a magnetic flux density sufficient to induce at least muscle contraction. A magnetic stimulation device as described in the U.S. patent application Ser. No. 14/789,156 or U.S. patent application Ser. No. 14/789,658, incorporated herein by reference, may be used.

The applicator for magnetic treatment may be placed proximate to the patient's body. The magnetic flux density may be applied into the target biological structure. Electric 5 current may be induced and treat the neuromuscular plate and/or the nerve innervating the at least one muscle fiber. The treatment may cause at least a partial muscle contraction.

Furthermore, the present invention discloses the advanced 10 approaches in aesthetic applications, e.g. for cellulite treatment and/or body shaping. Combined methods of treatment by electromagnetic field and treatment by magnetic field are used. The electromagnetic field may include treatment by radiofrequency, infrared or optical waves. The magnetic 15 treatment may be provided by permanent magnets, electromagnetic devices generating a static magnetic field or timevarying magnetic devices. In the preferred application the treatment by a pulsed magnetic field and radiofrequency treatment may be combined. However the application is not 20 limited by the recited combination so the combined method may include magnetic treatment and any treatment by electromagnetic field, e.g. light treatment, IR treatment or treatment by radiofrequency waves, e.g. microwaves, short waves or long waves. The magnetic treatment may also be 25 provided with thermal treatment, e.g. heating and/or cooling.

The transmatch and generator control unit 14 receives information from the operator via the control unit and regulates the operation of the HF generator 11 and the transmatch 12. The transmatch transmits HF to a balun 30 transformer 13, which converts unbalanced impedance to balanced impedance. This processed signal goes to two capacitive applicators 6, which may be positioned 0.5 cm or higher above the surface of the skin or applied on dielectric or insulating, non-conductive material which is in contact 35 with the skin surface.

A device described in U.S. patent application Ser. No. 14/278,756 incorporated herein by reference may be used for application of the present methods. The device may exclude the balun transformer, or the balun transformer may 40 be included in transmatch. The possible methods of treatment by combined methods are described below.

Magnetic treatment in combination with radiofrequency treatment may be applied by two independent treatment devices, e.g. one device for treating the biological structure 45 by radiofrequency waves and second device for treating the biological structure by magnetic field. Both devices may have a separate applicator for treating the biological structure, or one applicator may be used by at least two devices, i.e. the applicator may be modular for a plurality of devices. 50

The device may include at least one HF frequency generator for providing energy for radiofrequency treatment and for providing energy for magnetic treatment. In an alternative embodiment, the device may include at least one HF frequency generator for providing energy for radiofrequency 55 treatment and at least one other independent frequency generator for providing energy for magnetic treatment. The device may include plurality of applicators for providing separate radiofrequency or magnetic treatments to the patient.

In alternative embodiment the applicator may provide a combination of radiofrequency and magnetic treatment. In one embodiment, the applicator may include at least one radiofrequency electrode for providing radiofrequency treatment and at least one magnetic field generating device, e.g. 65 a coil, for providing magnetic treatment. In another embodiment, the applicator may include at least one electrode for

providing radiofrequency treatment and at least one magnetic field generating device providing magnetic treatment, wherein the at least one RF source provides energy for both at least one electrode and at least one magnetic field generating device.

In still another embodiment the at least one RF source may provide the energy for the at least one magnetic field generating device providing magnetic treatment wherein the at least one magnetic field generating device may be used as the at least one electrode. The essence is the far different stimulation frequencies which are used for RF treatment and magnetic treatment. The magnetic field generating device in the high frequency field is similar to the electrode. This enables the magnetic field generating device to be the electrode for radiofrequency treatment. In the preferred embodiment a flat coil may be used as the electrode.

The frequencies for the radiofrequency treatment may be in the range of ones of MHz to hundreds of GHz, more preferably in the range of 13 MHz to 3 GHz, most preferably around 13.56 or 40.68 or 27.12 MHz or 2.45 GHz. The term "around" should be interpreted as in the range of 5% of the recited value. The impulse frequencies for the magnetic treatment may be in the range of hundreds of Hz to hundreds of kHz, more preferably in the range of ones of kHz to tens of kHz, most preferably up to 10 kHz. However the repetition rate of the magnetic impulses may reach up to 700 Hz, more preferably up to 500 Hz, most preferably in the range of 1 to 300 Hz, e.g. at least 1, 5, 20, 30, 50, 100, 140 or 180 Hz. The magnetic flux density of the magnetic treatment may be at least 0.1, 0.8, 1, 1.5, 2, 2.4 or up to 7 Tesla on the coil surface (equivalent to 70000 Gauss). The treatment/ successive treatments may last several seconds, e.g. at least 5, 10, 30, 60, 120 or 240 seconds, or longer, e.g. at least 20, 30, 45, 60 minutes. The impulse duration may be in the range of 3 µs to 10 ms or more, or alternatively 3 µs to 3 ms or alternatively 3 µs to 1 ms. The impulse duration may be e.g. 3, 10, 50, 200, 300, 400, 500, 625, 1000, 2000 or 3000 μs. The duty cycle of the stimulation may be at least 1:50, more preferably at least 1:40, even more preferably at least 1:20, most preferably at least 1:8 or up to 1:4. The magnetic stimulation device may emit no radiation.

A derivative of the magnetic flux density is defined by Equation 4.

$$\frac{dB}{dt}$$
, Eq. 4

where: dB is magnetic flux density derivative [T]; dt is time derivative [s].

The maximal value of the magnetic flux density derivative may be up to 5 MT/s, preferably in the ranges of 0.3 to 800 kT/s, 0.5 to 400 kT/s, 1 to 300 kT/s, 1.5 to 250 kT/s, 2 to 200 kT/s, 2.5 to 150 kT/s. In exemplary applications the maximal value of the magnetic flux density derivative may be at least 0.3, 0.5, 1, 2.5, 3.2, 5, 8, 10, 17, 30 or 60 kT/s. The value of magnetic flux density derivative may correspond to induced current within the tissue.

The magnetic flux density derivative may be determined within the entire period of the magnetic signal and/or in any segment of the magnetic signal.

60

Alternatively the treatment device may include no deep muscle diathermy device for heating the target biological structure. The treatment preferably may include no electrode which may enable heating the biological structure in contact mode.

Cellulite is an effect of skin change resulting in orange peel appearance. The cause of the cellulite is orientation of collagen fibers in so called "fibrous" septae. The fibrous septae contract and harden over time creating a dimple effect. Additionally, blood and lymphatic vessels lack circulation due to the contraction and hardening of the septae. The lymph flow may be blocked resulting in swelling. Another cause of cellulite may be adipose cells protruding to dermis. Cellulite may be treated by the recited methods.

One application of time-varying magnetic field for 10 enhancing the visual appearance of body region may be treatment of a muscle by magnetic flux density for reducing the cellulite. The magnetic flux density may be delivered through the skin to the neuromuscular plate and/or nerve innervating at least one muscle fiber. The electric current 15 may be induced in the target biological structure causing at least partial muscle contraction. The at least partial muscle contraction may cause the movement of the skin and all the biological structures subtending epidermis. Additionally, the at least partial muscle contraction may improve blood cir- 20 culation by itself, or via the movement of the muscle in the vicinity including fibrous septae. Additionally, blood and/or lymph circulation may be improved in the layers subtending epidermis since the muscle contraction may move the fibrous septae. Also local and/or adipose tissue metabolism 25 may be improved.

The lymph flow may be improved by at least partial muscle contraction which may provide effect similar to manual massage. The improved lymph flow may improve local metabolism and/or immune system. The improved 30 lymph flow may contribute to purer lymph due to faster delivery of the lymph to the lymph nodes where the lymph may be cleared.

The present method may provide a massage effect via the treatment which may be caused by the at least partial muscle 35 contraction. Therefore the massage effect may be achieved by contactless methods instead of manual massage techniques or soft tissue techniques. The massage effect may improve lymph circulation.

In another aspect, improvement of functionality and/or 40 the appearance of the muscle may be achieved with results similar to body exercise. The results may be achieved by application of high magnetic flux density to the body region and inducing at least partial muscle contraction. Higher values of magnetic flux density applied may result in a 45 stronger muscle contraction. The patient may feel firmer and tighter.

With the present method muscle contractions induced by the applied magnetic flux density may help to tone the muscle providing a more attractive appearance. As the 50 muscle structure is treated by time-varying magnetic field the entire limb may be moved due to the high power of the magnetic treatment. Nevertheless, the method is not limited to the applications to the limbs and the method is able to treat any muscle, e.g. gluteus maximus or any muscle/deep 55 muscle to induce body contouring and/or body shaping effect and fat burn. Additionally, shortened and/or flabby muscles may be stretched. The physical fitness of the patient may be improved as well.

The magnetic field may treat various body regions, e.g. 60 thighs, buttocks, hips, abdomen or arms. The muscles may be shaped to enhance visual appearance of the treated body region. The body part may obtain enhanced visual appearance of its contour.

The magnetic field may treat at least one muscle of lower 65 limb, particularly the parts which are prone to cellulite such as thighs or saddlebags. The time-varying magnetic field

may induce at least partial muscle contraction in different muscle and/or muscle group. Following the position and/or orientation of the magnetic field generating device the anterior, posterior and/or medial compartment of the thigh may be treated. The anterior compartment includes sartorius muscle, rectus femoris muscle, vastus lateralis muscle, vastus intermedius muscle, vastus medialis muscle. Posterior compartment includes biceps femoris muscle, semitendinosus muscle and semimembranosus muscle. Medial compartment includes pectineus muscle, external obturator muscle, gracilis muscle, adductor longus muscle, adductor brevis muscle and adductor magnus muscle.

The treatment may cause circumferential reduction of thighs. Further the muscle may obtain enhanced visual appearance, thigh may be well-shaped. Thigh contour may be enhanced as well.

The at least one surrounding body region may be treated as well, e.g. buttocks.

The applicator may be placed within proximity of the patient's treated area. The applicator may be fixed to the patient. Alternatively the correct position may be provided by a mechanical arm and/or adjustable applicator. The applicator may be made of adhesive and/or high friction material at least on contact surface with the patient.

The magnetic field may be generated with a low repetition rate such as 1 Hz for a predetermined period of time, e.g. 30 seconds, sufficient for setting the applicator to a correct position where the treatment is most effective. During the period the magnetic flux density may be adjusted following the patient's needs to induce muscle contraction sufficiently strong and comfortable for the patient.

The treatment may start a treatment protocol. The treatment protocol may include a set of predetermined treatment sequences of predetermined repetition rates applied for predetermined time periods. The sequences may be repeated and/or adjusted following the patient's need. The sequence may include a repetition rate in the range of 1 to 100 Hz, preferably in the range of 2 to 90 Hz, more preferably in the range of 5 to 50 Hz, most preferably in the range of 10 to 45 Hz. The sequences may last at least 30, 45, 60, 90, 120 or up to 300 seconds.

Alternatively the treatment may include the only the treatment protocol without applying the magnetic field of low repetition rate. The correct position of the applicator and/or adjusting the magnetic flux density may be adjusted during the first sequence of the treatment protocol.

In one application, the treatment may induce the same effect as muscle exercising of buttocks. During the treatment of buttocks the magnetic field may be targeted to treat of muscles shaping the buttocks, e.g. tensor fasciae latae muscle or at least one of gluteal muscles: maximus, medius or minimus. In one preferred application all three gluteal muscles may be treated. Further other muscles may be treated, e.g. abdominal muscles, spinal muscles and/or thoracic muscles. By the complex treatment and muscle contraction in the body region the treated muscles may be strengthened, toned, the cellulite may be reduced and dimples may be removed. Buttocks and even the patient's figure may be enhanced in visual shape appearance and may become more attractive. Buttocks become well-shaped, round, firm, well-trained, toned, smoother, tight and lifted. The complex treatment may reduce hips, make perfect round and lifted buttocks, increasing the self-confidence of the patient

The treatment may be more efficient than standard workout in fitness since the fitness machines strengthen only the isolated muscles. The results may be achieved in very short-time periods with minimal time of treatment. Without being limited, it is believed that the exercising of the gluteus medius may reduce the volume of the buttocks; exercising of the gluteus maximus may shape and/or lift the buttocks; exercising of the gluteus minimus may lift the buttocks.

In the preferred application the magnetic treatment may be combined with other treatment methods using different approaches, e.g. conventional non-invasive treatments. The combined treatment may be applied to the surroundings tissues around buttocks to reduce the cellulite around the 10 buttocks and enhance the shape of the enhanced appearance of the buttocks. The surrounding tissues may be represented by e.g. abdomen, love handles, thighs or saddle bags.

The magnetic field may treat at least one muscle responsible for silhouette of the body. The time-varying magnetic 15 field may induce at least partial muscle contraction in different muscle and/or muscle group responsible for silhouette in the region of abdomen, love handles and/or bra fat. Following the position and/or orientation of the magnetic field generating device rectus abdominis muscle may 20 be treated. Alternatively latissimus dorsi muscle, abdominal internal oblique muscle, abdominal external oblique muscle, transverse abdominal muscle and/or pyramidalis muscle may be treated by the time-varying magnetic field.

The treatment may cause circumferential reduction in the 25 region of belly, hips and/or love handles. Alternatively the treatment may tighten at least one of these body parts. Further the muscles may obtain enhanced visual appearance, belly may be well-shaped. Repetitive application may even reach in a six-pack look. The at least one surrounding body 30 region may be treated as well, e.g. buttocks.

The magnetic field may treat at least one muscle of upper limb, particularly the parts which may be prone to cellulite such as arm. The time-varying magnetic field may induce at least partial muscle contraction. Following the position 35 and/or orientation of the magnetic field generating device the at least partial muscle contraction may occur in biceps brachii muscle, brachialis muscle, coracobrachialis muscle and/or triceps brachii muscle.

The treatment may cause circumferential reduction of the 40 arm. Further the muscle may obtain enhanced visual appearance, arm may be well-shaped. Arm contour may be enhanced as well.

The at least partial muscle contraction may be more efficient for adipose tissue metabolism as the value of 45 magnetic flux density increases since the muscle contraction may be stronger. The higher magnetic flux density may treat the higher number of muscle fibers contraction and the more adipose tissue may be reduced. Therefore the visual appearance of regions prone to cellulite may be enhanced. 50

Treatment by time-varying magnetic field may induce lipolysis. Adipose tissue may be reduced by decreasing the number and/or volume of adipose cells. Promoted adipose cell metabolism may increase as the value of magnetic flux density increases. The treatment may release free fatty acids 55 (FFA) from at least one adipose cell. The increased concentration of FFA may influence a homeostasis of the adipose cell. A disruption of the homeostasis may cause a dysfunction of the adipose cell. The dysfunction may be followed by stress for endoplasmic reticulum (ER stress). ER stress may 60 cause additional lipolysis and/or apoptosis of the at least one adipose cell.

Furthermore, ER stress may cause increase of intracellular calcium ions (Ca2+) which may promote an apoptotic process and may continue into controlled cell death of the 65 adipose cell. The apoptosis may be induced by Ca-dependent effectors, e.g. calpain or caspase-12. Endogenous

ligands or pharmacological agents, such as vitamin D, may induce prolonged cytosolic calcium increase. Vitamin D may influence release of Ca2+ from endoplasmic reticulum. Hence the effect of treatment may be enhanced by application of vitamin D and/or Ca2+ prior, during and/or after the treatment. The most significant effect may be achieved by application of both, Ca2+ and vitamin D, prior the treatment to provide all factors influencing adipose cell apoptosis.

Alternatively, increased level of Ca2+ may induce autophagy within adipose cell as well. Autophagy is selfeating process of cellular organelles to produce energy and it may proceed into cell death. Autophagy may be induced by ER stress or it may be induced via Ca2+ signaling.

FIG. 6 illustrates pathways which may induce apoptosis of the at least one adipose cell. FFA may accumulate in the at least one adipose cell (20). The magnetic field may induce lipolysis (21), i.e. a release of FFA from adipose tissue. Accumulated FFA may reach a threshold when adipose cell is unable to utilize FFA. A dysfunction of the adipose cell may occur. The adipose cell may react on the dysfunction by ER stress (22). ER stress may induce lipolysis hence additional release of FFA may occur (20). ER stress may cause apoptosis of the adipose cell (23). Furthermore, the ER stress may release Ca2+ (24) which may contribute the apoptosis (23).

The effect of the treatment by magnetic field for adipose tissue reduction may be influenced by various biological processes and/or pathways as recited above. The processes and/or pathways may be synergic hence the adipose tissue reduction may be accelerated and/or more efficient.

The method may cause the circumferential reduction i.e. a reduction of the size of the treated body region. The method may be mostly indicated for the regions with cellulite, particularly for thighs, buttocks, saddlebags, love handles, abdomen, hips and/or arms. However, the indication is not limited to the mentioned regions and the method may be used for treatment of any other body region.

Furthermore, the method may change BMI index of the patient. In a preferred application the BMI of the patient may be reduced. Alternatively, the BMI of the patient may increase.

# Heating/Cooling

The magnetic field may be combined with application of heat and/or cold. The body region may be heated/cooled. The target biological structures may be selectively treated due to different tolerance of various biological structures to heating/cooling. Applying of heat/cold may improve metabolism of the biological structure, alternatively a reduction of the biological structure may occur.

Various biological structures have a different tolerance to heating/cooling. Hence target biological structures may be remodeled, e.g. adipose cells may be selectively reduced. The cells different from adipose cells such as epidermal cells, are not reduced by the heating/cooling. The selective reduction of adipose cell may be caused by e.g. crystallization within adipose cells. The heating/cooling of the adipose cell may reduce the number and/or volume of adipose cells by lipolysis, apoptosis and/or necrosis.

Cooling

Although the following exemplary treatment describes applying cold to the patient, the treatment method is not limited to the exemplary application. The method may include heating the patient instead of cooling the patient.

The cooling may be provided in a contact, indirect contact and/or non-contact manner. Contact cooling may be provided by a cooling element placed to the proximity of the treated body region, e.g. a thermally conductive material

such as metal, gel or ice may be used. Indirect contact may be provided by a flow of cooling media within a layer of flexible and/or rigid material, e.g. cooling media such as glycerol, saline or water solution may be used. The cooling element may include a plurality of passages which the 5 cooling media may flow in. Non-contact cooling may be provided by radiant cooling. Alternatively cooling media may be applied directly on the body region. The cooling media used for non-contact heating/cooling may be preferably a fluid, e.g. a gas or liquid. The gas may be applied in 10 form of a spray, e.g. cold air, CO2 or N2 may be used. The cooling media may be at a predetermined temperature which may be controlled by the device to induce selective treatment of the target biological structure.

In an exemplary application the adipose cells may be 15 selectively treated by cooling. A cooling media may be applied to the body region. A reduction of adipose cell may be induced by cooling the adipose cell. The cells different from adipose cells are not reduced by the cooling. Temperature Ranges

The temperature of the cooling media and/or element may be less than the temperature of the patient's body. The temperature of cooling media may be at least -196° C. The temperature of the cooling element may be preferably in the range of 40 to -40° C., more preferably in the range of 20 25 to  $-20^{\circ}$  C., even more preferably in the range of 10 to  $-15^{\circ}$ C. or in the range of 5 to  $-10^{\circ}$  C. A temperature of the adipose cells may be above a freezing point of water to prevent a reduction of cells including water. The temperature of the adipose cells may be preferably in the range of 37 to 30  $-10^{\circ}$  C., more preferably in the range of 20 to  $-4^{\circ}$  C., even more preferably in the range of 15 to  $-2^{\circ}$  C. or around  $4^{\circ}$  C. The temperature of epidermis may be at least -40, -20, -10,15, 20, 35° C., more preferably the temperature of epidermis may be in the range of around 5 to  $-5^{\circ}$  C. The term around 35 may be interpreted to mean in the range of 10% of the particular value.

Alternatively the body may be heated by application of various treatment methods, e.g. radiofrequency, diathermy or optical waves. The temperature in the target tissue may be 40 up to 80° C., more preferably in the range of 37 to 60° C., even more preferably in the range of 39 to 50° C., most preferably in the range of 42 to 47° C. The temperature may be adjusted based on the intended use, e.g. adipose tissue reduction or collagen production.

The temperature of adipose cells may vary during the treatment. The temperature of the adipose cells may oscillate around a predetermined temperature. The temperature of the adipose cells may also follow a temperature profile in a predefined temperature range. The temperature and/or the 50 temperature range may be adjusted following the patient's needs.

Cycles

Alternatively the adipose cells may be heated prior, during and/or after cooling. The term "heat prior" refers to 55 preheating the adipose cells before cooling treatment. The term "heat during" refers to cyclically changing periods of cooling and heating the adipose cells during the treatment. The treatment may also include passive periods between heating and/or cooling. The term "passive period" refers to 60 applying neither heating nor cooling. The term "heat after" refers to applying heat after the cooling treatment. The periods of heating/cooling and/or passive periods may be adjusted following by the patient's need. Treatment Duration 65

The cooling may be applied for at least 10 seconds. Time duration of cooling the body region may be in the range of 1 to 240 minutes, more preferably in the range of 5 to 120 minutes, even more preferably 10 to 60 minutes, most preferably up to 30 minutes.

The cooling element and/or media may be applied continuously and/or in pulses. Continuous application may be used for a cooling element and/or media at a temperature above 0° C. Pulsed mode may be used for application of fluids below 0° C. The cooling may be provided cyclically for short periods in order of milliseconds, e.g. N2 may be applied cyclically to prevent damage to epidermis/dermis. The cooling element and/or media may be applied preferably non-invasively, e.g. by topical application. Alternatively the cooling element and/or media may be applied subcutaneously, e.g. injected.

Adjustable Applicator

The cooling element may correspond with the body region. The cooling element may be adjustable in shape to fit the body region. The cooling element may be made of flexible material to be modified in shape to follow the shape 20 and/or contour of the body region. A fitting of the cooling element may provide homogenous treatment and/or temperature distribution. Further the heat exchange may be optimized at the contacted surface. Pressure

A treatment may induce a thermal gradient in the body region, i.e. the shallow layer of the skin such as epidermis and/or dermis may have a lower temperature than the deeper layer such as adipose tissue. The effect of cooling may be improved by limiting and/or eliminating dermal blood flow. The dermal blood flow may be limited by applying vasoconstrictive medicine, preferably topically administered. Positive

The dermal blood flow may also be limited and/or eliminated by applying a pressure. The pressure greater than systolic blood pressure may be used for pushing the blood out of the dermal and/or subcutaneous veins. The deeper adipose cells may be cooled and/or the cooling of the adipose cells to the temperature sufficient to reducing the adipose cells may be reached in shorter time period. Furthermore appropriate contact of the cooling element may be provided by the pressure in case of contact treatment.

Negative

The treatment effect may also be enhanced by applying negative pressure to the skin below the applicator, e.g. a 45 convex cooling element may be used. The skin may be pulled towards the inner surface of the cooling element. Hence the contact may be enabled by applying negative pressure. Alternatively, the folded tissue may be pinched by two or more cooling elements and the cooling may be applied to the tissue, particularly to adipose cells. Further the skin may be stretched and a thickness of the skin may decrease. Skin thickness decrease may promote improved heat transfer to/from adipose cells.

Miscellaneous

The cooling may be applied with application mechanical treatment such as acoustic, ultrasound, and/or shockwave treatment to enable more homogenous treatment effect. The adipose cells reduction may also be promoted by physical movement of the body region by e.g. massaging, or vibrations. The pressure applied to the body region may vary to improve the results.

#### Protocols

An apoptotic index may increase after cooling the body region. The apoptotic index refers to a percentage of apoptotic cells in specimen. The apoptotic index may increase due to cooling up to ten times greater value compared with the value prior the cooling.

35

Based on the apoptotic index a treatment combining various methods may be designed as a tailor-made solution following the patient's need. The cooling may be applied to the body region of the patient prior, during and/or after applying a magnetic field to the patient. Pain Relief

A pain relieving medicament may be provided during the treatment if the patient is more sensitive to decreased temperature. A topical application may be preferred. The pain relief effect may be provided by a magnetic field of 10 repetition rate at least 100 Hz, more preferably 120 Hz, even more preferably at least 140 Hz or at least 180 Hz. The pain relieving effect may be provided before, during or after the treatment.

Precooling

Cooling the body region prior to applying the magnetic field may influence a metabolism of adipose cells. Alternatively, the cooling of the adipose cells may induce apoptosis, lipolysis, autophagy and/or disruption of the adipose cells. A release of FFA from adipose cells may induce ER stress as 20 recited above. The application of the magnetic field may cause at least partial muscle contraction reducing the adipose cells. Furthermore the released FFA from adipose cells influenced by cooling may be used as energy source for muscle work. Hence the cooling may be followed by treating 25 treatment, more preferably around 1 to 24 hours after a patient by magnetic field inducing at least partial muscle contraction. Due to the combined effect of cooling and magnetic treatment the adipose cells may be reduced in number and/or volume. Moreover the muscles may be shaped, tightened, strengthened and/or the volume of the 30 muscle may increase. Additionally, the cellulite appearance may be reduced due to muscle work.

The magnetic treatment may provide a massage effect. Hence blood and/or lymph flow may be improved. Additionally frozen tissue may be relaxed.

The combined magnetic treatment may be applied immediately after cooling, more preferably around 1 to 24 hours after cooling, e.g. 1, 2, 8 or 20 hours after cooling. The combined treatment may be applied periodically. Alternatively, the treatment by cooling and/or magnetic field may be 40 applied separately, e.g. treatments may alternate in appropriate periods. The period may last from 12 hours to 1 month, more preferably from 1 day to 2 weeks, most preferably from 3 days to 1 week.

In an exemplary application of the treatment method a 45 patient's body region may be cooled by a cooling element for e.g. at least 20 minutes up to 1 hour. After stopping the cooling the body region may be treated by magnetic field for e.g. 15 to 45 minutes.

Cooling

Cooling the body region may be applied simultaneously while the body region is treated by magnetic field within one treatment

The magnetic cooling may be provided to the patient while the patient is being treated by magnetic field.

Alternatively, cooling may alternate with treatment by magnetic field, i.e. the magnetic field is applied when cooling is not provided to the patient or vice versa. Periods of alternating cooling and magnetic treatment may vary.

The magnetic field may be preferably applied in burst 60 mode. Each burst contains train of magnetic impulses and a period of no magnetic treatment. The train may include a plurality of magnetic impulses. A number of magnetic impulses may vary in the range of at least 1 to 10000 impulses, more preferably in the range of at least 10 to 1000 65 impulses. The time duration of the train and/or the period of no magnetic treatment may vary in order of milliseconds to

order of seconds, e.g. in the range of 100 milliseconds to 100 seconds, more preferably in the range of 1 to 30 seconds, most preferably in the range of 5 to 15 seconds.

In one exemplary application the body region may be cooled for a period of e.g. at least 5 minutes. After stopping the cooling the body region may be treated by a magnetic field for a period of e.g. at least 5 minutes. After stopping the magnetic treatment the body region may be cooled. Post Cooling

The cooling may also be applied after magnetic treatment. The treatment by magnetic field may provide stimulation, pain relief and/or a myorelaxation effect for the treated body area before cooling. The cooling applied with pressure may be better accepted by the adipose tissue when the muscle below the adipose cells is relaxed. Alternatively the magnetic treatment may provide a temporary pain relief effect hence a patient suffering from a lower pain threshold, e.g. cool sensitivity, may be treated.

In an exemplary application the body region may be treated by a magnetic field for a period of e.g. at least 15, 20 or 30 minutes. After stopping the magnetic treatment the body region may be cooled.

The cooling may be applied immediately after magnetic magnetic treatment, e.g. 1, 2, 8 or 20 hours after magnetic treatment. The combined treatment may be applied periodically.

In an exemplary application of the treatment method a patient's body region may be treated by magnetic field for e.g. at least 20 minutes up to 1 hour. After stopping the magnetic treatment the body region may be treated by cooling for e.g. 15 to 45 minutes.

In the previously described exemplary treatment methods the cooling of the patient may be replaced by heating the patient.

FIGS. 7A and 7B illustrate an application of the treatment by a device providing heating/cooling to the body region of the patient 25. FIG. 7A illustrates a treatment device 26 including a connection to power source, a magnetic field generating device 27 and means for providing heating/ cooling 28, e.g. RF source or cooling element. FIG. 7B illustrates alternative treatment applied by two separate treatment devices, i.e. by a device providing magnetic treatment 29 and a device providing heating/cooling 30.

All the recited combined treatment methods may be provided by at least one applicator. The applicator may provide cooling and magnetic treatment. Alternatively one 50 applicator may provide cooling and second applicator may provide magnetic treatment.

The target structure may be treated by combined methods which may be used for remodeling the adipose tissue, body shaping and/or contouring, muscle toning, skin tightening, skin rejuvenation, wrinkle removing, reducing stretchmarks, breast lifting, lip enhancement or treatment of cellulite in general by application of electromagnetic radiation to target structure to selectively heat the target tissue to remove and/or remodel adipose tissue from the target tissue. The second approach is to transmit a magnetic treatment to the target structure, inducing at least partial muscle contraction within the target structure to remodel the adipose tissue by natural adipose tissue catabolism. Adipose tissue catabolism may be caused by apoptosis or necrosis of the adipocytes. The muscle contraction caused by induced eddy current is the same as a natural contraction. The adipose tissue may be reduced in natural way. Additionally, the muscle may be shredded in a natural way. Therefore the effect resulting in body shaping and/or contouring may be significantly improved.

The combination of the recited method may improve currently used applications in various aspects and the effect 5 of the treatments may be significantly enhanced. The application of a radiofrequency electromagnetic field may be combined with application of a magnetic field applied before, simultaneously or after the radiofrequency treatment. The application of a magnetic field may induce many 10 benefits for radiofrequency treatment, such as applications inducing at least partial muscle contraction, myorelaxation effect or analgesic effect. The perfusion or metabolism may be improved as well.

The at least partial muscle contraction may induce 15 enhanced effects on adipose tissue reduction by catabolism of the adipose tissue and burning energy from adipose tissue. The total adipose tissue reduction effect may be enhanced by radiofrequency treatment.

Additionally, the at least partial muscle contraction may 20 improve a blood flow and/or perfusion in the treated body region. The improved blood flow may be caused by activation of muscle pump and/or by the muscle necessity of more oxygen due to the at least partial contraction. The blood flow may increase rapidly and it may last temporarily, preferably 25 up to 1 hour, more preferably up to 45 minutes, most preferably up to 30 minutes. Due to increased blood flow and/or local perfusion, the risk of overheated muscle may be limited or even eliminated. Further the homogeneity of the thermal field induced by thermal effect of radiofrequency 30 treatment may be significantly enhanced and/or the temperatures may be well-balanced/compensated in the target body region. Still another benefit may be prevention of creation any hot spot caused by steep thermal gradient.

Due to improved blood flow, perfusion and/or lymph flow 35 the metabolism may be improved. Additionally, the effect of radiofrequency treatment may be enhanced by improved metabolism, e.g. cellulite treatment, body shaping and/or contouring, skin tightening or skin rejuvenation. Further benefit may be reducing or eliminating the risk of pannicu- 40 litis or local skin inflammation since any clustering of the treated adipocytes may be prevented by the improved metabolism. The improved blood and/or lymph flow may contribute the removing of the adipocytes. The removing of the adipocytes may be promoted by higher number of cells 45 phagocytosing the adipocytes as well. Synergic effects of magnetic and RF treatment may significantly improve metabolism. Therefore the possibility of adverse event occurrence may be limited and treatment results induced by the present invention may be reached in shorter time period. 50

Further the at least partial muscle contraction may improve the movement of lymphatic vessel and the lymph flow may be improved.

In the preferred application the RF and/or magnetic field may be modulated. In the most preferred application both 55 treatments are modulated. The magnetic treatment may be modulated in the magnetic flux density domain, repetition rate domain, or impulse duration domain, to provide different treatment effects and to prevent adaptation of the target biological structure. The radiofrequency treatment may be 60 modulated in the frequency domain, intensity domain and/or time domain to reach the most complexity and/or efficiency of the target treated biological structure. The modulation in the time domain may be changing the active and passive periods of stimulation, e.g. the radiofrequency treatment 65 may include period with no stimulation, i.e. the radiofrequency treatment may be not continual but the treatment

may be provided in pulses. The periods of no stimulation may vary and may be adjusted by the operator. Due to modulation during the treatment, different target biological structures may be treated in the different depth.

The application may be contact or in the preferred application the treatment may be applied contactless. Contactless application may avoid all biocompatibility factors which may occur during contact treatment. In the most preferred application the treatment may be provided by self-operated device. Hence the applicator and/or magnetic field generating device need not be guided by the operator. The applicator may be fixed at a sufficient distance from the patient's skin enabling safe treatment for the patient. Self-operated treatment may be provided by a hand-held applicator or the applicator may be fixed to stand-alone device. The selfoperated treatment may be also enabled using various types of sensors in communication with the device for monitoring the treatment and/or the patient. The at least one sensor may be e.g. reactive sensor, electrochemical sensor, biosensor, biochemical sensor, temperature sensor, sorption sensor, pH sensor, voltage sensor, sensor for measuring distance of applicator from the patient surface and/or from the treated area, position sensor, motion detector, photo sensor, camera, sound detector, current sensor, sensor for measuring of specific human/animal tissue and/or any suitable sensors measuring biological parameters and/or combination thereof such as sensor for measuring dermal tensile forces, sensor for measuring the activity of the muscle, muscle contraction forces, tissue impedance or skin elasticity.

Further the homogeneity of the treatment may be improved by several approaches. A first approach may be represented by a moveable applicator providing the dynamic treatment to a large target area. The dynamic treatment may improve the homogeneity of applied treatment energy and additionally due to large area the effect is uniform and/or well balanced. Static positioning of the applicator may be used as well. Another approach of improving homogeneity may be represented by using a bolus. The bolus may provide improved transmittance of the electromagnetic energy to the treated biological structures. Additionally, the bolus may prevent occurrence of hot spots within the treated area; the bolus may provide constant temperature to the target treated surface area; or the bolus may increase the homogeneity of the radiofrequency waves application by providing a homogenous medium for electromagnetic waves propagation not being influenced by the interface of the target treated area and an air. The bolus may profile the electromagnetic field to enhance the effect of the treatment. In still another approach an air gap may be between the applicator and the patient.

The treatment by magnetic and/or electromagnetic field may be in continuous or discrete mode. In one application the magnetic treatment may be applied in continual mode with no pauses and the electromagnetic treatment may be applied in pulsed mode to provide improved adipose tissue reduction caused by natural process and by the increased temperature. In another application the electromagnetic treatment may be applied continuously with no pauses and the magnetic treatment may be applied in pulsed mode to provide improved thermal reduction of adipose tissue and by improved metabolism due to improved blood flow. Both modes may be combined in various treatment sequences.

In the preferred application the treatment may be started at the moment when the target biological structure reaches the predetermined temperature. The temperature in the target tissue may be up to  $80^{\circ}$  C., more preferably in the range of 37 to  $60^{\circ}$  C., even more preferably in the range of 40 to  $45^{\circ}$ 

C. The temperature may be adjusted based on the intended use, e.g. adipose tissue reduction, collagen production or muscle contraction. In an alternative application the intended use may be coagulation and/or ablation. The temperature in the target biological structure may be measured 5 by invasive method, e.g. using an invasive probe; or by contact method, e.g. using thermocouple sensor; or by contactless method, e.g. using infrared sensor or camera. The temperature of the target biological structure may be determined by a mathematic method. The sensor for measuring the temperature in the target biological structure may be attached to the applicator.

A benefit of the application of magnetic treatment and electromagnetic treatment may be causing an analgesic effect of the application and providing a possibility of 15 treating a patient with higher sensitivity for thermal effects induced by electromagnetic treatment, i.e. patients with any predisposition inducing increased thermal sensitivity. The analgesic effect may be induced by magnetic treatment by suitable repetition rates and it may be induced immediately 20 during the magnetic treatment. The analgesic effect may last up to several hours after magnetic treatment. The magnetic flux density of the magnetic treatment may preferably reach at least motor-threshold intensity inducing at least partial muscle contraction therefore the homogeneity of the thermal 25 field may be significantly enhanced.

Another benefit of application the magnetic treatment may be causing a myorelaxation effect. The magnetic treatment may be applied on spastic muscle structures to relieve the hypertonus of the muscle and improving the blood 30 and/or lymph flow. Therefore relieving the hypertoned muscle may contribute to the analgesic effect and contribute to the acceptability of the treatment by the patient.

The blood and/or lymph flow may be limited in the spastic muscles and the metabolism may be limited as well, meaning that the risk of clustering the treated target structures may be higher and possible adverse events may occur. The recited risks may be eliminated by the used of magnetic treatment.

In one aspect of the invention, the treatment by magnetic 40 field may be applied to the target structure before the radiofrequency treatment to prepare the target structure for following treatment by radiofrequency field. The effect of magnetic treatment may be to induce at least partial muscle contraction or to treat a muscle structure to increase a 45 muscular tonus of the target structure. Both effects may provide a massage effect for the structure within the proximity of the target structure hence the blood and/or lymph circulation may be improved to promote local metabolism. The temperature may be locally increased by the improved 50 blood flow and the target structure may accept the following radiofrequency treatment at significantly higher quality. Additionally, the collagen and/or elastin fibers may be remodeled or restored and/or its neogenesis may be improved to provide a younger, smoother, firmer and 55 enhanced skin appearance.

Additionally, previous application may improve acceptability of the electromagnetic field by increasing the temperature of the skin and the transmittance of the electromagnetic field may be improved due to less value of skin <sup>60</sup> impedance. Further the radiofrequency may penetrate deeper target structures relative to treatment without a preceding magnetic treatment of the target structure and/or area.

Another benefit may be releasing the adipose tissue in the 65 muscle by muscle contraction and/or by temperature increase causing better liquidity of adipose tissue. Still

another benefit of the at least partial muscle contraction may be mechanical breaking large adipose tissue bulks into smaller bulks which may be easier metabolized and/or the smaller adipose tissue bulks may be removed faster by the lymphatic and/or blood flow. Due to improved metabolism and/or circulation the cellulite may be treated in a short time and the visual effect on skin appearance may be significantly enhanced.

In another aspect of the invention, the treatment by magnetic field may be applied to the target structure simultaneously with the radiofrequency treatment to improve effects of the electromagnetic treatment inducing heat in the target structure.

The simultaneous application of magnetic treatment and radiofrequency treatment may be in two modes: a first mode may generate the magnetic impulses while radiofrequency treatment is active or another mode may generate radiofrequency treatment while the magnetic treatment is not in an active stimulation period, i.e. the period of magnetic treatment and radiofrequency treatment alternates. Both modes amplify the resulting effect of the treatment. Therefore the results may be achieved in significantly shorter time than the same results achieved by separate applications of the radio frequency and magnetic treatments.

The simultaneous method of magnetic treatment and radiofrequency treatment of the target tissue may increase the peak magnetic component of the entire treatment resulting in improved heating of the target structure including containing higher water volume, e.g. skin. Due to increased temperature of skin, the production and/or remodeling of collagen and/or elastin fibers may be improved and the skin may be provided with a younger, smoother, firmer and enhanced appearance. The effect of overheating the muscle may be reduced by the improved blood flow.

In still another aspect of the invention, the treatment by magnetic field may be applied to the target structure after the treatment by electromagnetic field to enhance and/or contribute to the effects of radiofrequency treatment by influencing the target structure by magnetic field.

The magnetic field may treat the target structure to cause at least partial muscle contraction proximate to the target structure to improve blood flow and provide homogenous temperature distribution at high quality after creating a temperature distribution at lower quality by radiofrequency treatment.

All of the methods may be provided by the above recited technical solutions. The above mentioned methods may be used separately or in any combination.

The method may cause the circumferential reduction i.e. a reduction of the size of the treated body region. The method may be mostly indicated for the regions with cellulite, especially for buttocks, saddlebags, love handles, abdomen, hips, thighs or arms. However, the indication is not limited to the mentioned regions and the method may be used for treatment of any other body region.

The at least one applicator may include at least one magnetic field generating device. The plurality of magnetic field generating devices may be positioned in isolated locations of the at least one applicator. Alternatively, the magnetic field generating devices may be positioned next to each other, in an array or matrix, in a pattern or in randomized locations of the at least applicator.

The magnetic field generating devices may be positioned and/or moved in the at least one applicator in one plane; in at least two mutually tilted planes defined by a convex or concave angle, or perpendicular to each other; or in at least two parallel planes with the at least one magnetic field

generating device in each parallel plane. The movement of the at least one magnetic field generating device may be translational and/or rotational, constant or accelerated. The movement may follow a predetermined, random or predefined trajectory, such as a pattern, array or matrix. The 5 movement of the at least one applicator may be handled in similar manner as the movement of the at least one magnetic field generating device. The angles of the planes and/or the movement of the at least one magnetic field generating device may be adjusted by an operator following the 10 patient's needs. The positioning may be provided by mechanical holder, enabling tilting, distancing and positioning magnetic field generating device in various planes. In an alternative embodiment the patient may be positioned in the intersection of the magnetic fields generated by the plurality 15 of magnetic field generating devices. In the preferred application the at least one applicator may be movable and the movement may be circular.

The plurality of magnetic field generating devices may be positioned within one applicator having form of mechanical 20 holder. The shape of the applicator having form of mechanical holder may be adjustable, e.g. the applicator may include at least one moveable part. In a preferred embodiment the applicator having form of mechanical holder may provide spatial arrangement of the energy delivery elements in one 25 axis, two axes or three axes and/or provide tilting and/or rotation. The applicator having form of mechanical holder may provide fixation of the at least one magnetic field generating device in one position. The moveable parts may be connected by sliding mechanism and/or by a joint mecha- 30 nism. An exemplary embodiment of such an applicator may be found in U.S. Pat. No. 9,468,774, incorporated herein by reference. The applicator may be adjustable following the body region and/or biological structure.

The static position of the at least one applicator may be 35 provided by a positioning member. The positioning member may be e.g. an arm or an adjustable flexible belt. The positioning member may include a buckle for adjusting the length of the belt. The applicator may be placed within predefined locations of the belt. Alternatively the applicator 40 may be shaped to be moveable along the positioning member, e.g. the shape of the applicator may be preferably concave, e.g. V-shaped or U-shaped. The positioning member may be inserted itself into the concavity of the applicator. The position of the applicator may be adjusted by limited 45 movement along the positioning member because the positioning member may be used as guiding member. However, the applicator may not be fixed to a particular static position. The position of the applicator may be dynamically adjusted during the treatment following the patient's needs. The 50 position of the applicator may be adjusted manually by the operator, or automatically by the treatment device. In one exemplary embodiment a plurality of applicators may be used for treating larger body regions, e.g. buttocks, abdomen or thigh.

The present methods may also induce muscle contraction to reduce effect of skin laxity. Skin laxity may be caused by e.g. aging process or increasing number and/or volume of adipose cells which pulls down the skin by gravity, rapid weight loss or skin stretching during the pregnancy. The 60 muscles may be treated by the induced electric current to contract. Repetitive contractions may cause the muscles to obtain the tonus and flexibility. Therefore the skin appearance may be enhanced by treating the flabby muscles. The effect of skin tightening may be achieved. The method also 65 may promote the collagen and elastin fibers in the layers subtending the epidermis hence the skin may obtain

enhanced visual appearance. The method may be widely applied but not limited to application to the regions of neck, breasts, arms or abdomen. The method may provide the smoother and younger appearance of the skin to the patient.

Similar methods of the muscle structure treatment by time-varying magnetic field for inducing the at least partial muscle contraction may be used for treatment of wrinkles as well. Wrinkles are results of extrinsic and intrinsic factors. Nowadays, wrinkles are considered to be negative effect of natural aging process which decreases the production of collagen and elastin fibers and weakens the skin which becomes thinner. As the muscle treatment by the magnetic flux density may induce at least partial muscle contraction, the collagen and elastin fibers neogenesis may be improved. Additionally, the muscles subtending the treated region may be toned and the skin may obtain a younger and enhanced visual appearance. Therefore, the effect of skin tightening may be achieved.

Wrinkles may be prevented or reduced by practicing facial exercises which may cause a massage effect to the facial tissues, improving blood and lymph circulation. Additionally, the facial muscles may be relaxed and toned after the exercise. A similar effect as facial exercise may be achieved by non-invasive and/or contactless method of treating the facial muscles by magnetic flux density. Further additional advantage of the present method may be the improvement of restoration of the collagen and elastin fibers, more effective toning and strengthening of the facial muscles.

The present methods may improve the neogenesis and remodeling of collagen fibers in the lips to reach a full, plump and firmer appearance. The magnetic flux density may be applied to the lips by an applicator. Therefore the lips may become fuller and firmer without any need of invasive method such as injection of the synthetic fillers, permanent makeup or the facial implants. The present method may promote the remodeling and/or neogenesis of collagen fibers in a natural way. Additionally, the collagen is natural substance of the human body which may provide the elasticity to the structure.

The present methods may be used for enhancing the visual appearance of breasts. Cooper's ligament may be treated, improved and/or firmed by the at least partial muscle contraction. The treatment may induce the elevation of the breast tissue. Additionally, the breast tissue may be treated to be modified in a shape, wherein the shape includes the size and/or the contour of the breast tissue. Therefore the visual appearance may be enhanced and breasts may be more attractive for the patient. The present method may be a non-invasive alternative for current aesthetic surgery method for the treatment of sagging breast tissue. The present method may provide a patient a method of breast visual appearance enhancement without surgery. Therefore the method lacks post-surgery complications such as scars, 55 postoperative pain or long recovery period. Various treatment protocols may be used.

Following the recited methods the treatment may be but is not limited to continuous, pulsed, randomized or burst. The impulse may be but not limited to monophasic, polyphasic, biphasic and/or static magnetic field. In the preferred application the magnetic impulse may be in biphasic regime, i.e. it is consisted of two phases, preferably positive and negative.

In the preferred application of the present method the trains of pulses, called bursts are used.

Repetition rate and/or magnetic flux density may vary during the treatment protocol. Further the treatment may

25

55

include several periods of different repetition rates, therefore the modulation may be in repetition rate domain. The treatment may include several periods of different magnetic flux densities, therefore the modulation may be in magnetic flux density domain. Alternatively the treatment may include different impulse durations, therefor the modulation may be in impulse duration domain. In yet another approach the treatment may be modulated by any combinations thereof.

Various envelopes and/or waveforms, e.g. pulse, sinusoidal, rectangular, square, triangular, saw-tooth, trapezoidal, exponential etc. for the purpose of muscle treatment may also be used, and are not limited to recited shapes.

The values of magnetic flux density and repetition rate are cited in several preferred applications since the perception of 15 the treatment is subjective. Nevertheless, the magnetic flux density and repetition rates are not limited by the recited values. A person skilled in the physical therapy is able to repeat and apply the treatment methods adjusting the magnetic flux density and/or repetition rate following the 20 patient's sensitivity or needs.

The present method is not limited to be used independently. For enhancing the result the method may be used in combination with other conventional non-invasive and/or invasive aesthetic treatment method.

All the recited methods may be applied to a patient in a non-invasive and/or contactless way. Therefore the present methods provide an effective alternative approach of enhancing the visual appearance with no need of invasive treatment or surgery. Further, the visual results are appreciable after several treatments. Additionally, the results include not only the visual appearance enhancement but even the improvement of the muscle structures, hence the patient feels firmer and tighter. The muscle structures become toned with no need of any diet or spending time by 35 exercising in fitness.

The patient may feel firmer and/or tighter. The skin may be also tighter. Additionally, adipose tissue reduction may occur. Furthermore, cellulite may be reduced as well.

Thus, novel systems and methods have been described. 40 Various changes and substitutions may of course be made without departing from the spirit and scope of the invention. The invention, therefore, should not be limited, except by the following claims and their equivalents.

The following U.S. patent applications are incorporated <sub>45</sub> herein by reference: Ser. Nos. 14/873,110; 14/926,365; 14/951,093; 15/073,318; 15/099,274; 15/151,012; 15/178, 455; 15/396,073; 15/446,951; 15/404,384 and 15/473,390.

Thus, novel apparatus and methods have been shown and described. Various changes and substitutions may of course 50 be made without departing from the spirit and scope of the invention. The invention, therefore, should not be limited, except by the following claims and their equivalents.

The invention claimed is:

1. A method for treating a patient, comprising:

- positioning a first applicator having a first magnetic field generating device disposed within it, the first applicator being in contact with a body region of the patient;
- positioning a second applicator having a second magnetic field generating device disposed within it, the second applicator being in contact with the body region of the patient; 60 comprising comprises a buckle. 9. The method of claim 7, furth an unintended event has occurr from a sensor measuring one of
- securing each applicator at the body region of the patient in mutually tilted planes defined by an angle via a belt; 65 charging a first energy storage device;

charging a second energy storage device;

- discharging energy from the first energy storage device to the first magnetic field generating device to generate a first time-varying magnetic field;
- discharging energy from the second energy storage device to the second magnetic field generating device to generate a second time-varying magnetic field;
- simultaneously applying each of the time-varying magnetic fields to a muscle of the patient in the body region in order to contract the muscle; and
- cooling adipose cells in the patient to a temperature in a range of  $15^{\circ}$  C. to  $-2^{\circ}$  C.

**2**. The method of claim **1**, wherein the first and second time-varying magnetic fields each have a magnetic flux density in a range of 0.5 T and up to 7 T, a repetition rate in a range of 1 Hz to 700 Hz, an impulse duration in a range of  $3\mu$ s to 10000  $\mu$ s, and a maximal value of a magnetic flux derivative in a range of 2.5 kT/s to 150 kT/s, and wherein the body region comprises the patient's buttocks or abdomen.

**3**. The method of claim **1**, further comprising cooling the first magnetic field generating device with a cooling media.

**4**. The method of claim **1**, further comprising measuring with a sensor one or more of a voltage, a current, a phase shift, a magnetic flux density, or a temperature; and

adjusting the first time-varying magnetic field in response to the measurement.

5. The method of claim 1, further comprising determining an unintended event has occurred based on measurements from a sensor, wherein the unintended event comprises a hardware error or a metal object being within proximity of the first or second applicator.

6. The method of claim 1, wherein the belt is flexible.

7. A method of toning or firming a patient's muscles using a treatment device, comprising:

- placing an applicator in contact with a body region of the patient, wherein the applicator houses a magnetic field generation device, and wherein the body region comprises one or more of thighs, buttocks, or abdomen;
- using a belt to maintain the applicator's position within the body region;
- charging an energy storage device via an energy source; discharging energy from the energy storage device to the magnetic field generating device, such that a timevarying magnetic field is generated, the time-varying magnetic field comprising magnetic pulses;
- applying bursts of the magnetic pulses to muscle fibers, neuromuscular plates, or nerves innervating the muscle fibers, each burst comprising a first duration wherein a plurality of subsequent magnetic pulses are generated in a trapezoidal envelope, and a second duration wherein no magnetic pulses are generated, wherein the treatment duty cycle of the bursts is at least 10% in order to achieve toning or firming of the body region of the patient, wherein the time-varying magnetic field comprises a magnetic flux density between 0.1 T and 7 T, a repetition rate between 1 Hz and 700 Hz, an impulse duration between 3 µs and 10000 µs, and a maximal value of a magnetic flux derivative between 2.5 kT/s and 150 kT/s.

**8**. The method of claim 7, wherein the belt further comprising comprises a buckle.

**9**. The method of claim **7**, further comprising determining an unintended event has occurred in response to a signal from a sensor measuring one or more of voltage, current, phase shift, or magnetic flux density of a hardware component.

**10**. The method of claim 7, further comprising evaluating a signal from a hardware component of the treatment device

15

35

55

60

and providing at least one maximal treatment parameter comprising one or more of magnetic flux density, repetition rate, or impulse duration to an operator in response to one or more treatment parameters set by the operator.

**11**. The method of claim **7**, further comprising applying radiofrequency waves to the body region, wherein the magnetic field generating device generates both the time-varying magnetic field and the radiofrequency waves.

**12**. A treatment device for toning at least one muscle of a patient using a time-varying magnetic field, the treatment device comprising:

an applicator configured to be held in contact with a body region of the patient with a belt, the applicator housing

a magnetic field generating device within a casing; an energy storage device;

- means for discharging energy from the energy storage device to the magnetic field generating device such that impulses of the time-varying magnetic field are generated, the time- varying magnetic field having a biphasic shape with a repetition rate in between 1 Hz and 700 Hz, an impulse duration between 3 μs to 10000 μs, and a maximal value of a magnetic flux derivative between 2.5 kT/s to 150 kT/s; and
- means for cooling the magnetic field generating device by 25 a fluid cooling media,
- wherein the belt is configured to aid in positioning the applicator in order to apply the time-varying magnetic field with at least motor-threshold magnetic flux density to a peripheral neural system innervating the at 30 least one muscle of the patient in order to repetitively contract the at least one muscle within the body region such that the at least one muscle is toned, the body region comprising one of buttocks or abdomen.
- 13. The device of claim 12, further comprising:

a high-frequency generator;

a balun transformer; and

means for converting an unbalanced radiofrequency signal to a balanced radiofrequency signal in order to generate radiofrequency waves, wherein the radiofrequency waves are configured to be applied to the body region.

14. The device of claim 13, further comprising a transmatch; and

means for matching the impedance of the radiofrequency 45 signal.

15. The device of claim 12, further comprising:

- a sensor configured to measure one or more of voltage, current, phase shift, magnetic flux density, or temperature of a hardware component of the device; 50
- means for evaluating a signal from the sensor; and means for providing at least one maximal treatment parameter comprising one or more of magnetic flux density, repetition rate, and impulse duration to an operator such that the magnetic field generating device does not overheat, wherein the at least one maximal treatment parameter is based in part on at least another

treatment parameter set by the operator. 16. The device of claim 12, further comprising a sensor, wherein the device is configured to use a signal from the sensor in order to determine an unintended event including

a hardware error or a metal object within proximity of the

device and the device is configured to disable generating the time-varying magnetic field in the case of determining the unintended event.

17. The device of claim 16, further comprising a second applicator housing a second magnetic field generating device, wherein a first time-varying magnetic field generated by the first magnetic field generating device and a second time-varying magnetic field generated by the second magnetic field generating device is based in part on the signal from the sensor.

**18**. A treatment device for toning muscles of a patient using time-varying magnetic fields, the treatment device comprising:

- a first applicator configured to be coupled to a body region of the patient, wherein the first applicator houses a first magnetic field generation device, and wherein the body region comprises one or more of thighs, buttocks, or abdomen;
- a second applicator configured to be coupled to the body region of the patient, wherein the second applicator houses a second magnetic field generation device;
- a first energy storage device configured to be charged by an energy source;
- a second energy storage device configured to be charged by the energy source;
- means for discharging energy from the first energy storage device to the first magnetic field generating device and discharging energy from the second energy storage device to the second magnetic field generating device, respectively, such that a first time-varying magnetic field and a second time-varying magnetic field is generated, each of the time-varying magnetic fields comprising magnetic pulses,
- wherein the device is configured to apply bursts of the magnetic pulses to muscle fibers, neuromuscular plates, or nerves innervating the muscle fibers, each burst comprising a first duration wherein a plurality of subsequent magnetic pulses are generated and a second duration wherein no magnetic pulses are generated, wherein the treatment duty cycle of the bursts is at least 10%, wherein the time-varying magnetic fields each comprise a magnetic flux density between 0.1 T and 7 T, a repetition rate between 1 Hz and 700 Hz, an impulse duration between 3 µs and 10000 µs, and a maximal value of a magnetic flux derivative between 2.5 kT/s and 150 kT/s.

**19**. The device of claim **18**, further comprising means for determining an unintended event has occurred in response to a signal from a sensor measuring one or more of voltage, current, phase shift, or magnetic flux density of a hardware component.

20. The device of claim 18, further comprising means for evaluating a signal from a hardware component of the treatment device and for providing at least one maximal treatment parameter comprising one or more of magnetic flux density, repetition rate, and impulse duration to an operator in response to one or more treatment parameters set by the operator.

**21**. The device of claim **18**, wherein each of the magnetic field generating devices are configured to generate radiof-requency waves configured to be applied to the body region.

\* \* \* \* \*